D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340
E: cs@solitaire.in
P: 020 6716 6716 W: dskcirp.com

Date: 20th November, 2026

To,

Listing Department,
BSE Limited,
Floor 25, P. J. Towers,
Dalal Street, Mumbai – 400001

Listing & Compliance Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai - 400051

Reference: SCRIP Code: 523890 Security Symbol: DSKULKARNI ISIN: INE891A01022

Subject: Newspaper Advertisement regarding Un-audited Standalone & Consolidated Financial Results for the Quarter Ended on September 30, 2026.

Dear Sir/Madam,

Pursuant to Regulation 47 of Chapter IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper advertisements for un-audited Standalone & Consolidated Financial Results for the quarter ended on September 30, 2026, published in a national newspaper- 'Business Standard' and a regional newspaper-'Navrashtra' as per further details below:

- 'Business Standard' (all editions except Ahemdabad) published on 13th November 2026;
- 'Business Standard' (Ahemdabad edition) published on 14th November 2026; and
- 'Navrashtra' (all editions) on 13th November 2026.

We request you to take the same on record.

Thanking you,
Yours faithfully,
For, D S Kulkarni Developers Limited

BHUSHAN VILAS PALRESHA
Digitally signed by BHUSHAN VILAS PALRESHA
Date: 2026.11.20 18:09:43 +05'30'

Bhushan Vilas Palresha
Managing Director
DIN: 01258918

Encl: Newspaper advertisement published.

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly follow-ing the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subse-quent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION
- NAION, a rare condition, affects one in 10,000 people annually
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-au mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghost-face, Chucky, characters from Five Nights at Freddy's 2 and Fi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a re-creation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-be acter conceived by its creator. Such original characters, or OCs, take cosplay beyond rec-OC reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Priitee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

BAFNA PHARMACEUTICALS LIMITED

CIN: L24294TN1995PLC030698

Regd. Off: No.299, Thambu Chetty Street, Chennai-600 001, Tel: 044 - 2526 7517 / 2527 0992 / Fax: 044 25261264, E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

Extracts of Unaudited Financial Results for the Quarter And Half Year ended September 30, 2026.

(Rs. In Lakhs) Except EPS

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4,766.56	2,658.32	3,546.82	7,424.88	7,009.22	15,061.74
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,109.98
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	690.90	13.59	307.87	704.49	642.14	1,134.31
6	Equity Share Capital	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
7	Other Equity as per the Audited Balance Sheet of the previous year (excluding Revaluation Reserve)	-	-	-	8,489.62	6,757.16	7,249.32
8	Earnings Per Share Basic :	2.89	0.03	1.32	2.93	2.75	4.69
	Diluted :	2.89	0.03	1.32	2.93	2.75	4.69

Note: i). The above is an extract of the detailed Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of SEBI (LODR) Regulations, 2015. The detailed Results are available on the website of the Stock Exchanges and on the Company's website. The Results can also be accessed by scanning the below QR Code. **ii).** The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2026.

For BAFNA PHARMACEUTICALS LIMITED
SD/-
S Hemalatha
Whole Time Director
(DIN: 02714329)

Place: Chennai
Date: 11.11.2026

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340

Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038

Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Palresha
Managing Director
DIN: 01258918

Date: 12th November, 2026
Place: Pune

Navigate the market's twists and turns

Take a deep dive into a stock or sector with Compass in Business Standard, and gain insights into the trends, triggers, and shifts that could shape market movements ahead.

Business Standard Insight Out

RANE HOLDINGS LIMITED

Regd. Office : "MAITHRI", 132, Cathedral Road, Chennai - 600 086

visit us at: www.ranegroup.com CIN: L35999TN1936PLC002202

Extract of unaudited consolidated financial results for the quarter and half year ended September 30, 2026

Rs. Lakhs

S. No	Particulars	Quarter ended		Half Year ended	
		September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
		Unaudited	Unaudited	Unaudited	Unaudited
1.	Total Income	189,760	140,983	349,447	275,537
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	4,608	4,830	10,416	9,609
3.	Net Profit / (Loss) for the period before tax (after Exceptional items)	38,823	4,669	44,881	10,994
4.	Net Profit / (Loss) for the period after tax and Exceptional items	31,955	3,126	36,782	8,875
5.	Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax)]	32,094	2,562	36,756	8,183
6.	Equity Share Capital	1,428	1,428	1,428	1,428
7.	Earnings per share (EPS) (face value - Rs.10/- each) (not annualised for quarters and year to date periods)				
	Basic (in Rs.)	140.97	16.45	167.15	52.01
	Diluted (in Rs.)	140.32	16.45	166.76	52.01

1. The above Unaudited financial results were reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on November 12, 2026.
2. The full results are available on the website at the link - https://ranegroup.com/investors/rane-holdings-limited/?rhl-fin-3

QR Code :

For Rane Holdings Limited
L Ganesh
Chairman & Managing Director

Place : Chennai
Date : November 12, 2026

DECCAN CEMENTS LIMITED

CIN: L26942TG1979PLC002500

Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad, Telangana - 500 082.

Ph: 040-23310168, **Email**: secretarial@deccancements.com, **Website**: www.deccancements.com

Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026

(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42
2	Net Profit for the period (before Tax and Exceptional items)	(1872.28)	(722.00)	1246.57	(2594.29)	3293.14	2141.02	(1872.62)	(722.24)	1246.22	(2594.86)	3292.61	2139.71
3	Net Profit for the period before tax (after Exceptional items)	(1644.80)	(949.49)	1246.57	(2594.29)	3293.14	3425.09	(1645.14)	(949.72)	1246.22	(2594.86)	3292.61	3423.78
4	Net Profit for the period after tax (after Exceptional items)	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2859.12	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2857.81
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2909.06	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2907.75
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs. 5/- each)												
	1. Basic	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40
	2. Diluted	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40

Notes

a) The above Standalone and Consolidated results for the quarter ended and half year ended 30th September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12th November, 2026.

b) The above is an extract of the detailed format of Standalone and Consolidated financial results filed for the quarter ended and half year ended 30th September 2026 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd (www.nseindia.com) and also on the Company's website (www.deccancements.com).

for **DECCAN CEMENTS LIMITED**
Sd/-
P Parvathi
Chairperson and Managing Director
DIN:00016597

Place: Hyderabad
Date : November 12, 2026

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly follow-ing the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subsequent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION
- NAION, a rare condition, affects one in 10,000 people annually
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-au mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghostface, Chucky, characters from Five Nights at Freddy's 2 and Pi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a recreation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-be acter conceived by its creator. OCs, take cosplay beyond rec-OC reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Pritee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

BAFNA PHARMACEUTICALS LIMITED

CIN: L24294TN1995PLC030698

Regd. Off: No.299, Thambu Chetty Street, Chennai-600 001, Tel: 044 - 2526 7517 / 2527 0992 / Fax: 044 25261264, E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

Extracts of Unaudited Financial Results for the Quarter And Half Year ended September 30, 2026.

(Rs. In Lakhs) Except EPS

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4,766.56	2,658.32	3,546.82	7,424.88	7,009.22	15,061.74
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,109.98
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	690.90	13.59	307.87	704.49	642.14	1,134.31
6	Equity Share Capital	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
7	Other Equity as per the Audited Balance Sheet of the previous year (excluding Revaluation Reserve)	-	-	-	8,489.62	6,757.16	7,249.32
8	Earnings Per Share Basic :	2.89	0.03	1.32	2.93	2.75	4.69
	Diluted :	2.89	0.03	1.32	2.93	2.75	4.69

Note: i). The above is an extract of the detailed Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of SEBI (LODR) Regulations, 2015. The detailed Results are available on the website of the Stock Exchanges and on the Company's website. The Results can also be accessed by scanning the below QR Code. ii).The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2026.

For BAFNA PHARMACEUTICALS LIMITED
SD/-
S Hemalatha
Whole Time Director
(DIN: 02714329)

Place: Chennai
Date: 11.11.2026

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340

Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038

Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Palresha
Managing Director
DIN: 01258918

Date: 12th November, 2026
Place: Pune

Navigate the market's twists and turns

Take a deep dive into a stock or sector with Compass in Business Standard, and gain insights into the trends, triggers, and shifts that could shape market movements ahead.

Business Standard Insight Out

RANE HOLDINGS LIMITED

Regd. Office : "MAITHRI", 132, Cathedral Road, Chennai - 600 086
visit us at: www.ranegroup.com CIN: L35999TN1936PLC002202

Extract of unaudited consolidated financial results for the quarter and half year ended September 30, 2026

Rs. Lakhs

S. No	Particulars	Quarter ended		Half Year ended	
		September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
		Unaudited	Unaudited	Unaudited	Unaudited
1.	Total Income	189,760	140,983	349,447	275,537
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	4,608	4,830	10,416	9,609
3.	Net Profit / (Loss) for the period before tax (after Exceptional items)	38,823	4,669	44,881	10,994
4.	Net Profit / (Loss) for the period after tax and Exceptional items	31,955	3,126	36,782	8,875
5.	Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax)]	32,094	2,562	36,756	8,183
6.	Equity Share Capital	1,428	1,428	1,428	1,428
7.	Earnings per share (EPS) (face value - Rs.10/- each) (not annualised for quarters and year to date periods)				
	Basic (in Rs.)	140.97	16.45	167.15	52.01
	Diluted (in Rs.)	140.32	16.45	166.76	52.01

1. The above Unaudited financial results were reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on November 12, 2026.
2. The full results are available on the website at the link - https://ranegroup.com/investors/rane-holdings-limited/?rhl-fin-3

QR Code :

For Rane Holdings Limited
L Ganesh
Chairman & Managing Director

Place : Chennai
Date : November 12, 2026

DECCAN CEMENTS LIMITED

CIN: L26942TG1979PLC002500

Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad, Telangana - 500 082.

Ph: 040-23310168, **Email**: secretarial@deccancements.com, **Website**: www.deccancements.com

Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026

(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42
2	Net Profit for the period (before Tax and Exceptional items)	(1872.28)	(722.00)	1246.57	(2594.29)	3293.14	2141.02	(1872.62)	(722.24)	1246.22	(2594.86)	3292.61	2139.71
3	Net Profit for the period before tax (after Exceptional items)	(1644.80)	(949.49)	1246.57	(2594.29)	3293.14	3425.09	(1645.14)	(949.72)	1246.22	(2594.86)	3292.61	3423.78
4	Net Profit for the period after tax (after Exceptional items)	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2859.12	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2857.81
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2909.06	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2907.75
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs. 5/- each)												
	1. Basic	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40
	2. Diluted	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40

Notes

a) The above Standalone and Consolidated results for the quarter ended and half year ended 30th September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12th November, 2026.

b) The above is an extract of the detailed format of Standalone and Consolidated financial results filed for the quarter ended and half year ended 30th September 2026 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd (www.nseindia.com) and also on the Company's website (www.deccancements.com).

for DECCAN CEMENTS LIMITED
Sd/-
P Parvathi
Chairperson and Managing Director
DIN:00016597

Place: Hyderabad
Date : November 12, 2026

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly following the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subsequent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION
- NAION, a rare condition, affects one in 10,000 people annually
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-au mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted Ho sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company (T behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghostface, Chucky, characters from Five Nights at Freddy's 2 and Fi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a recreation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-be acter conceived by its creator. Such original characters, or OCs, take cosplay beyond rec-OC reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Pritee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

— TENDER CARE — — Advertorial

BANK OF BARODA INAUGURATES SPECIALISED SME BRANCH IN VIJAYAWADA TO ACCELERATE MSME GROWTH IN THE STATE

Bank of Baroda, India's International Bank, inaugurated its new Specialized SME Branch at Vijayawada, in NTR District, reaffirming its commitment to strengthening the MSME sector and supporting the economic development of Andhra Pradesh.



The branch was formally inaugurated by Shri Sunil Kumar Sharma, CGM – MSME Banking, Co-lending & SCF, Corporate Office, Mumbai, in the presence of Shri M V S Sudhakar, General Manager & Zonal Head, Hyderabad Zone, and Shri S K Kiran Reddy, Deputy General Manager & Regional Head, Vijayawada Region, along with local business leaders, community representatives and valued customers.

The branch assumes special significance given Vijayawada's strategic proximity to Amaravati, the upcoming capital city of Andhra Pradesh, which is poised to emerge as a major hub for infrastructure, commercial and economic activities.

Addressing the gathering, Shri Sunil Kumar Sharma, CGM, Bank of Baroda, stated that the specialized branch aims to provide comprehensive financial solutions, including working capital, term loans, project finance and customised credit facilities to existing and aspiring entrepreneurs. He further highlighted that the branch would cater to the diverse business potential of the Vijayawada–Guntur–Amaravati region, covering sectors such as infrastructure and construction, agro and food processing, rice mills, chilli and turmeric industries, textiles and handlooms, aquaculture, engineering, manufacturing, logistics, healthcare and hospitality.

DCIL REPORTS STRONG Q2 PROFITABILITY TURNAROUND; EBITDA RISES 58.58% YEAR-ON-YEAR

Dredging Corporation of India Limited (DCIL), a leading dredging company in India, has reported a significant improvement in financial performance for the quarter ended 30 September 2026 (Q2 FY 2026–27), marking a turnaround in profitability compared with the corresponding quarter of the previous financial year. The Company's performance reflects its unwavering commitment to operational excellence, efficient fleet deployment, prudent financial management and sustainable value creation, resulting in a significant turnaround in profitability while reinforcing its leadership in India's dredging sector.

During Q2 FY 2026–27, income from operations undertaken by DCIL's own dredgers increased by 23.08% to ₹198.66 crore, compared with ₹161.41 crore in Q2 FY 2025–26. Total revenue, including subcontract revenue and other income, stood at ₹211.83 crore, compared with ₹213.37 crore in the correspond-ing quarter. The Company recorded EBITDA of ₹41.69 crore, an increase of 58.58% over ₹26.29 crore in the corresponding quarter of the previous year. Profit Before Tax (PBT) improved to ₹7.51 crore from a loss of ₹33.06 crore, while Profit After Taxto (PAT) stood at ₹7.31 crore against a loss of ₹34.17 crore, representing a year-on-year improvement of ₹41.48 crore.

For the half-year ended 30 September 2026, total revenue rose to ₹568.29 crore from ₹456.43 crore in the corresponding peri-to od of FY 2025–26. EBITDA increased to ₹104.60 crore from ₹74.26 crore, while PAT improved to ₹18.54 crore from a loss of ₹57.51 crore in the previous-year period.

CHIEF MINISTER V. D. SATHEESAN TO INAUGURATE THE CENTENARY CELEBRATIONS OF DHANLAXMI BANK ON NOVEMBER 14TH

Kerala's historic Dhanlaxmi Bank is entering its centenary year, marking 100 years of banking excellence. The bank's year-long centenary celebrations will officially commence on November 14th. Chief Minister V. D. Satheesan will inaugurate the celebrations at 6 PM at the Hyatt Regency Hotel in Thrissur. The event will bring together dignitaries, representatives from industrial and social sectors, customers, current employees and alumni. As part of the milestone event, the bank will announce a scholarship scheme tailored for financially underprivileged students who demonstrate academic excellence. At a press conference held today at the Thrissur Press Club, Dhanlaxmi Bank MD & CEO Ajith Kumar K.K. and Executive Director P. Suryaraj were present and outlined the bank's future plans.



Headquartered in Thrissur, Dhanlaxmi Bank was established on November 14, 1927. Holding the distinction of being the oldest surviving bank in Kerala today, it enters its centenary year backed by record achievements in both total business volume and overall profitability.

UNION BANK OF INDIA CELEBRATES ITS 108TH FOUNDATION DAY

Union Bank of India proudly celebrated its 108th Foundation Day on November 11, 2026. The Bank was established on 11th November 1919. The Foundation Day was observed with celebrations at all the offices and branches across the country including our Telangana State. On the occasion a commemorative function was organized at Hyderabad by Union Bank of India, Zonal Office, Hyderabad marking over a century of trust, innovation, and excellence in banking services.

At Hyderabad City, the celebration was graced by the following distinguished guests

1.Shri Jayesh Ranjan, IAS, Spl Chief Secretary, Govt. of Telangana Telangana

2.Shri Vikas Raj, IAS, Spl Chief Secretary, Govt. of Telangana Telangana

3.Smt Divya, IAS, Commissioner, Rural Development, Govt. of Telangana Telangana



4.Shri Rajeswara Rao, Former Deputy Governor, Reserve Bank of India

5.Shri Chinmay Kumar, Regional Director, Reserve Bank of India, Hyderabad

Apart from above other senior executives of State Bank of India, Canara Bank, Bank of India, Punjab National Bank were also present along with Union Bank of India employees, customers, pensioners, valued stakeholders, and distinguished guests.

The event witnessed the presence of Shri M Ravindra Babu, Chief General Manager & Zonal Head of Hyderabad Zone Telangana State, Union Bank of India. Shri Sarvesh Ranjan, Chief General Manager, Reconciliation Dept. Central Office along with senior officials, employees and esteemed customers of the bank.

LGB FORGE LIMITED

Registered Office: 6/16/13 Krishnarayapuram Road, Ganapathy, Coimbatore-641 006
Tel: 0422-2532325 E-mail: secretarial@lgbforge.com Website: www.lgbforge.com
CIN: L27310TZ2006PLC012830

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30.09.2026 Rs. In Lakhs

Particulars	Quarter ended			Half Year ended		Year ended
	30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1 Total Income from operations	3,441.85	2,806.91	2,603.42	6,248.76	5,367.63	10,318.66
2 Net Profit/(loss) for the period (before tax, Exceptional and/or Extraordinary items)	-27.91	24.80	-72.65	-3.11	15.47	-152.39
3 Net Profit/(loss) for the period before tax (after Exceptional and/or Extraordinary Items)	-27.91	1,030.32	-72.65	1,002.41	15.47	-221.73
4 Net Profit/(loss) for the period after tax (after Exceptional and/or Extraordinary Items)	-27.91	1,030.32	-72.65	1,002.41	15.47	-221.73
5 Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive income (after tax)]	-27.91	1,030.32	-72.65	1,002.41	15.47	-201.64
6 Equity Share Capital	2,382.02	2,382.02	2,382.02	2,382.02	2,382.02	2,382.02
7 Earnings Per Share (of Re.1/- each) (*not annualised)						
(a) Basic	-0.01*	0.43*	-0.03*	0.42*	0.01*	-0.09
(b) Diluted	-0.01*	0.43*	-0.03*	0.42*	0.01*	-0.09

Note:
1 The above is an extract of the detailed format of Quarterly/Half year ended Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Half year ended Financial Results are available on the website of the Stock Exchange on which shares of the Company are listed (i.e.) www.bseindia.com and also available on the Company's website www.lgbforge.com. The same can also be accessed by scanning the QR code given below.

Place : Coimbatore
Date : 11.11.2026

By Order of the Board
for LGB FORGE LIMITED
RAJSRI VIJAYAKUMAR
MANAGING DIRECTOR
DIN : 00018244

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340
Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038
Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

Date: 12th November, 2026
Place: Pune

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Palresha
Managing Director
DIN: 01258918

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly follow-ing the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subse-quent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION
- NAION, a rare condition, affects one in 10,000 people annually
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghost-face, Chucky, characters from Five Nights at Freddy's 2 and Fi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a re-creation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-be acter conceived by its creator. Such original characters, or OCs, take cosplay beyond rec-OC reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Pritee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

BAFNA PHARMACEUTICALS LIMITED

CIN: L24294TN1995PLC030698

Regd. Off: No.299, Thambu Chetty Street, Chennai-600 001, Tel: 044 - 2526 7517 / 2527 0992 / Fax: 044 25261264, E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

Extracts of Unaudited Financial Results for the Quarter And Half Year ended September 30, 2026.

(Rs. In Lakhs) Except EPS

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4,766.56	2,658.32	3,546.82	7,424.88	7,009.22	15,061.74
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,109.98
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	690.90	13.59	307.87	704.49	642.14	1,134.31
6	Equity Share Capital	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
7	Other Equity as per the Audited Balance Sheet of the previous year (excluding Revaluation Reserve)	-	-	-	8,489.62	6,757.16	7,249.32
8	Earnings Per Share Basic :	2.89	0.03	1.32	2.93	2.75	4.69
	Diluted :	2.89	0.03	1.32	2.93	2.75	4.69

Note: i). The above is an extract of the detailed Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of SEBI (LODR) Regulations, 2015. The detailed Results are available on the website of the Stock Exchanges and on the Company's website. The Results can also be accessed by scanning the below QR Code. ii).The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2026.

For BAFNA PHARMACEUTICALS LIMITED
SD/-
S Hemalatha
Whole Time Director
(DIN: 02714329)

Place: Chennai
Date: 11.11.2026

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340

Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038

Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Palresha
Managing Director
DIN: 01258918

Date: 12th November, 2026
Place: Pune

Navigate the market's twists and turns

Take a deep dive into a stock or sector with Compass in Business Standard, and gain insights into the trends, triggers, and shifts that could shape market movements ahead.

Business Standard Insight Out

RANE HOLDINGS LIMITED

Regd. Office : "MAITHRI", 132, Cathedral Road, Chennai - 600 086
visit us at: www.ranegroup.com CIN: L35999TN1936PLC002202

Extract of unaudited consolidated financial results for the quarter and half year ended September 30, 2026

Rs. Lakhs

S. No	Particulars	Quarter ended		Half Year ended	
		September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
		Unaudited	Unaudited	Unaudited	Unaudited
1.	Total Income	189,760	140,983	349,447	275,537
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	4,608	4,830	10,416	9,609
3.	Net Profit / (Loss) for the period before tax (after Exceptional items)	38,823	4,669	44,881	10,994
4.	Net Profit / (Loss) for the period after tax and Exceptional items	31,955	3,126	36,782	8,875
5.	Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax)]	32,094	2,562	36,756	8,183
6.	Equity Share Capital	1,428	1,428	1,428	1,428
7.	Earnings per share (EPS) (face value - Rs.10/- each) (not annualised for quarters and year to date periods)				
	Basic (in Rs.)	140.97	16.45	167.15	52.01
	Diluted (in Rs.)	140.32	16.45	166.76	52.01

1. The above Unaudited financial results were reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on November 12, 2026.
2. The full results are available on the website at the link - https://ranegroup.com/investors/rane-holdings-limited/?rhl-fin-3

QR Code :

For Rane Holdings Limited
L Ganesh
Chairman & Managing Director

Place : Chennai
Date : November 12, 2026

DECCAN CEMENTS LIMITED

CIN: L26942TG1979PLC002500

Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad, Telangana - 500 082.

Ph: 040-23310168, **Email**: secretarial@deccancements.com, **Website**: www.deccancements.com

Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026

(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42
2	Net Profit for the period (before Tax and Exceptional items)	(1872.28)	(722.00)	1246.57	(2594.29)	3293.14	2141.02	(1872.62)	(722.24)	1246.22	(2594.86)	3292.61	2139.71
3	Net Profit for the period before tax (after Exceptional items)	(1644.80)	(949.49)	1246.57	(2594.29)	3293.14	3425.09	(1645.14)	(949.72)	1246.22	(2594.86)	3292.61	3423.78
4	Net Profit for the period after tax (after Exceptional items)	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2859.12	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2857.81
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2909.06	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2907.75
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs. 5/- each)												
	1. Basic	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40
	2. Diluted	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40

Notes

a) The above Standalone and Consolidated results for the quarter ended and half year ended 30th September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12th November, 2026.

b) The above is an extract of the detailed format of Standalone and Consolidated financial results filed for the quarter ended and half year ended 30th September 2026 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd (www.nseindia.com) and also on the Company's website (www.deccancements.com).

for DECCAN CEMENTS LIMITED
Sd/-
P Parvathi
Chairperson and Managing Director
DIN:00016597

Place: Hyderabad
Date : November 12, 2026

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly follow-ing the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subse-quent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION
- NAION, a rare condition, affects one in 10,000 people annually
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-au mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghost-face, Chucky, characters from Five Nights at Freddy's 2 and Pi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a re-creation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-b acter conceived by its creator. Such original characters, or OCs, take cosplay beyond rec-O reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Priitee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

pnb पंजाब नैशनल बैंक punjab national bank
the name you can BANK upon!
(A GOVERNMENT OF INDIA UNDERTAKING)

SAM BRANCH, DELHI, 4th FLOOR, 7th BHIKAJI CAMA PLACE, NEW DELHI-110066
EMAIL ID: zs8343@pnb.co.in

POSSESSION NOTICE
[Rule 8(1)]
(For Immovable property/ies)

Whereas, the undersigned being the Authorized Officer of the **Punjab National Bank** under the Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 and in exercise of powers conferred under section 13 (12) read with Rule 3 of the Security Interest (Enforcement) Rules 2002, issued a Demand Notice dated **22.05.2026** in the account of **M/S Shri Tirupati Industries** calling upon the Borrowers/Guarantors/Mortgagors:

Borrowers/Guarantors/Mortgagors as per Demand notice dated 22.05.2026 by Punjab National Bank (E-OBC)

M/s Shri Tirupati Industries (through its Proprietor Mr. Vishal Bansal) Address: Registered Office – 3rd Floor, Office No.322, Ganpati Plaza, MI Road, Jaipur, Rajasthan-302001. **Also, at Factory Office –** Khasra No.2133, Dudu Tehsil, Mozamabad, Ajmer Road, Jaipur-303008. **Also, at Godown –** Gram Dehri Kalan, Patwar Halka Dahmi Kalan, Bagru, Sanganer, Jaipur-303007.

Smt. Nikita Bansal- (Guarantor/Mortgagor) Address- Residence flat no. 903 & 1003, Akshat Durlabh, C-Scheme, Jaipur- 302001 **Also, at-** B-98, Saket Colony, Adarsh Nagar, Jaipur, Rajasthan – 302004.

M/s Futuristic Software Solutions Pvt. Ltd. (Guarantor/Mortgagor) (CIN no. U72200RJ1999PTC070006) Through its Directors Sh. Kapil Jaipuria and Rajesh Jaipuria. Address- 618, 6th Floor, Vaibhav Cine Multiplex, Vaishali Nagar, Jaipur Rajasthan 302021 **Also, at:** B-9, Shiv Marg, Banipark, Jaipur

Mr. Vishal Bansal (Guarantor/Mortgagor) Address - Residence flat no. 903 & 1003, Akshat Durlabh, C-Scheme, Jaipur- 302001

M/s Sneh Enterprises Through its Prop. Smt. Nikita Bansal (Guarantor/Mortgagor) Address- B-98, Saket Colony, Adarsh Nagar, Jaipur, Rajasthan – 302004. **Residence-** Flat no. 203, Akshat Trishala, C-57, Mahaveer Marg, Scheme, Jaipur- 302001

to repay the amount mentioned in the notice being **Rs. 34,30,85,565.78 (Rupees Thirty-Four Crore Thirty Lac Eighty-Five Thousand Five Hundred Sixty-Five and Paisa Seventy-Eight only)** as on 22.05.2026 along with further interest and other charges, if any thereon, within 60 days from the date of notice.

The Borrowers/Guarantors/Mortgagors having failed to repay the amount, notice is hereby given to the Borrowers/Guarantors/Mortgagors and the public in general that the undersigned has taken Possession of the property described herein below in exercise of powers conferred on him/her under Sub-Section (4) of Section 13 of act read with rule 8 of the security interest Enforcement rules 2002 on 9th day of November of the year 2026.

The Borrowers/Guarantors/Mortgagors in particular and the public in general are hereby cautioned not to deal with the property mentioned here under and any dealings with the said property will be subject to the charge of the **Punjab National Bank** for an amount **Rs. 34,30,85,565.78 (Rupees Thirty-Four Crore Thirty Lac Eighty-Five Thousand Five Hundred Sixty-Five and Paisa Seventy-Eight only)** along with further interest thereon.

The Borrower's/guarantor's/mortgagor's attention is invited to provision of sub-section (8) of section 13 of the Act, in respect of time available, to redeem the secured assets.

DESCRIPTION OF THE IMMOVABLE PROPERTY

S.No.	Security description
1.	A security interest created in favour of bank -First Charge by way of EM over no. 24 & 25 (Office no. 424 & 425) Situated on 4th Floor, Ganpati Plaza, on Mirza Ismail Road (M.I. Road), Jaipur, total admeasuring area 1914 feet (Built up area of each shop is 957 Sq. ft.) owned by Mr. Vishal Bansal. Boundaries- North: Office No. 426, South: Office No. 423, East: Corridor, West: Open to sky.
2.	A security interest created in favour of bank First charge by of EM, all part & of the commercial/ industrial Converted and Building at No. 239/1, Village-Barroni, Tehsil -Tonk. District-Tonk (Admeasuring 16282 Sq. mtr) owned by Sh. Vishal Bansal Boundaries- North: 20 ft Road, South: Agriculture, East: Agriculture, West: Agriculture.
3.	A security interest created in favour of bank First charge by way of EM over Residential Plot No. B-38, Niji Khatedari Scheme- Akshat Kanota Estate. Village -Kanota, Teh. Bassi, Jaipur (Admeasuring area 350.93 Sq. mtr. /419-72 Sq. Yard) owned by Smt. Nikita W/o Shri Vishal Bansal, Boundaries- North: Property No. B 63, South: 30 ft Road, East: Property No. B 39, West: 30 ft Road.
4.	A security interest created in favour of bank First charge by Way of EM over at Part & Parcel of the Commercial/industrial Convened property Situated at Khasra No. 1844, 1845, 8213/8194 and 8219/8192. Village Dudu. Tehsil- Dudu, Jaipur (Admeasuring area 9800 Sq. mtr.) owned by M/s Sneh Enterprises through its Proprietor Nikita Bansal. Boundaries- North: part of this property, South: part of this property, East: 15 ft Road, West: Agriculture Land.
5.	A security interest created in favour of bank First charge by way of EM over All Part & Parcel of the property situated on Plot No. 11/OC(i)/15, at ring road project, Village Newta, tehsil Sanganer. Jaipur (Admeasuring area 627 Sqm. Mtr.) owned by M/s Futuristic Software Solutions Pvt Ltd. Boundaries- North: Plot no. 11/OC(i)14, South: Plot no. 11/OC(i) 16 East: Road, West: Road.
6.	A security interest created in favour of bank First Charge by Way of EM over commercial/industrial converted land Situated at Khasra No. 1880 (area 4500 Sq. Mtr), 1881 (area 2000 sq Mtr), 1941 (1000 Sq. Mtr.), 8518/8216 (2500 Sq. Mtr.) Total Admeasuring area of property 10000 Sq. Mtr. at village Dudu. Panchayat & Tehsil Dudu owned by Smt. Nikita Bansal w/o Shri Vishal Bansal Boundaries- North: Agriculture land, South: Rohit Poly Foams Pvt. Ltd. East: Agriculture Land, West: 15 ft Road.

Date : 09.11.2026, Place : Jaipur **Punjab National Bank (Authorised Officer)**

Chart the path forward for with influential market mark voices

Decode markets with candid conversations and insightful Q&As featuring voices shaping business, markets, and economy. Every Monday in Business Standard.

Business Standard
Insight Out

D S KULKARNI DEVELOPERS LIMITED
CIN: L45201PN1991PLC063340
Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038
Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Palresha
Managing Director
DIN: 01258918

Date: 12th November, 2026
Place: Pune

DECCAN CEMENTS LIMITED
CIN: L26942TG1979PLC002500
Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad, Telangana - 500 082.
Ph: 040-23310168, **Email:** secretarial@deccancements.com, **Website:** www.deccancements.com

Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026

(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42
2	Net Profit for the period (before Tax and Exceptional items)	(1872.28)	(722.00)	1246.57	(2594.29)	3293.14	2141.02	(1872.62)	(722.24)	1246.22	(2594.86)	3292.61	2139.71
3	Net Profit for the period before tax (after Exceptional items)	(1644.80)	(949.49)	1246.57	(2594.29)	3293.14	3425.09	(1645.14)	(949.72)	1246.22	(2594.86)	3292.61	3423.78
4	Net Profit for the period after tax (after Exceptional items)	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2859.12	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2857.81
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2909.06	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2907.75
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs. 5/- each)												
	1. Basic	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40
	2. Diluted	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40

Notes

a) The above Standalone and Consolidated results for the quarter ended and half year ended 30th September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12th November, 2026.

b) The above is an extract of the detailed format of Standalone and Consolidated financial results filed for the quarter ended and half year ended 30th September 2026 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd (www.nseindia.com) and also on the Company's website (www.deccancements.com).

for **DECCAN CEMENTS LIMITED**
Sd/-
P Parvathi
Chairperson and Managing Director
DIN:00016597

Place: Hyderabad
Date : November 12, 2026

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly follow-ing the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subse-quent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION
- NAION, a rare condition, affects one in 10,000 people annually
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghost-face, Chucky, characters from Five Nights at Freddy's 2 and Fi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a re-creation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-be acter conceived by its creator. OCs, take cosplay beyond rec-OC reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Priitee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

BAFNA PHARMACEUTICALS LIMITED

CIN: L24294TN1995PLC030698

Regd. Off: No.299, Thambu Chetty Street, Chennai-600 001, Tel: 044 - 2526 7517 / 2527 0992 / Fax: 044 25261264, E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

Extracts of Unaudited Financial Results for the Quarter And Half Year ended September 30, 2026.

(Rs. In Lakhs) Except EPS

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4,766.56	2,658.32	3,546.82	7,424.88	7,009.22	15,061.74
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,109.98
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	690.90	13.59	307.87	704.49	642.14	1,134.31
6	Equity Share Capital	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
7	Other Equity as per the Audited Balance Sheet of the previous year (excluding Revaluation Reserve)	-	-	-	8,489.62	6,757.16	7,249.32
8	Earnings Per Share Basic :	2.89	0.03	1.32	2.93	2.75	4.69
	Diluted :	2.89	0.03	1.32	2.93	2.75	4.69

Note: i). The above is an extract of the detailed Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of SEBI (LODR) Regulations, 2015. The detailed Results are available on the website of the Stock Exchanges and on the Company's website. The Results can also be accessed by scanning the below QR Code. **ii).** The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2026.

Place: Chennai
Date: 11.11.2026

For BAFNA PHARMACEUTICALS LIMITED
SD/-
S Hemalatha
Whole Time Director
(DIN: 02714329)

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340

Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038

Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

Date: 12th November, 2026
Place: Pune

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Patresha
Managing Director
DIN: 01258918

Navigate the market's twists and turns

Take a deep dive into a stock or sector with Compass in Business Standard, and gain insights into the trends, triggers, and shifts that could shape market movements ahead.

Business Standard Insight Out

RANE HOLDINGS LIMITED

Regd. Office : "MAITHRI", 132, Cathedral Road, Chennai - 600 086

visit us at: www.ranegroup.com CIN: L35999TN1936PLC002202

Extract of unaudited consolidated financial results for the quarter and half year ended September 30, 2026

Rs. Lakhs

S. No	Particulars	Quarter ended		Half Year ended	
		September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
		Unaudited	Unaudited	Unaudited	Unaudited
1.	Total Income	189,760	140,983	349,447	275,537
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	4,608	4,830	10,416	9,609
3.	Net Profit / (Loss) for the period before tax (after Exceptional items)	38,823	4,669	44,881	10,994
4.	Net Profit / (Loss) for the period after tax and Exceptional items	31,955	3,126	36,782	8,875
5.	Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax)]	32,094	2,562	36,756	8,183
6.	Equity Share Capital	1,428	1,428	1,428	1,428
7.	Earnings per share (EPS) (face value - Rs.10/- each) (not annualised for quarters and year to date periods) Basic (in Rs.) Diluted (in Rs.)	140.97 140.32	16.45 16.45	167.15 166.76	52.01 52.01

1. The above Unaudited financial results were reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on November 12, 2026.
2. The full results are available on the website at the link - https://ranegroup.com/investors/rane-holdings-limited/?rhl-fin-3

QR Code :

Place : Chennai
Date : November 12, 2026

For Rane Holdings Limited
L Ganesh
Chairman & Managing Director

DECCAN CEMENTS LIMITED

CIN: L26942TG1979PLC002500

Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad, Telangana - 500 082.

Ph: 040-23310168, **Email**: secretarial@deccancements.com, **Website**: www.deccancements.com

Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026

(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42
2	Net Profit for the period (before Tax and Exceptional items)	(1872.28)	(722.00)	1246.57	(2594.29)	3293.14	2141.02	(1872.62)	(722.24)	1246.22	(2594.86)	3292.61	2139.71
3	Net Profit for the period before tax (after Exceptional items)	(1644.80)	(949.49)	1246.57	(2594.29)	3293.14	3425.09	(1645.14)	(949.72)	1246.22	(2594.86)	3292.61	3423.78
4	Net Profit for the period after tax (after Exceptional items)	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2859.12	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2857.81
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2909.06	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2907.75
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs. 5/- each)												
	1. Basic	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40
	2. Diluted	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40

Notes

a) The above Standalone and Consolidated results for the quarter ended and half year ended 30th September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12th November, 2026.

b) The above is an extract of the detailed format of Standalone and Consolidated financial results filed for the quarter ended and half year ended 30th September 2026 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd (www.nseindia.com) and also on the Company's website (www.deccancements.com).

Place: Hyderabad
Date : November 12, 2026

for **DECCAN CEMENTS LIMITED**
Sd/-
P Parvathi
Chairperson and Managing Director
DIN:00016597

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly follow-ing the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subse-quent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION
- NAION, a rare condition, affects one in 10,000 people annually
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-au mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghostface, Chucky, characters from Five Nights at Freddy's 2 and Pi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a re-creation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-be acter conceived by its creator. Such original characters, or OCs, take cosplay beyond rec-OC reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Priitee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

BAFNA PHARMACEUTICALS LIMITED

CIN: L24294TN1995PLC030698

Regd. Off: No.299, Thambu Chetty Street, Chennai-600 001, Tel: 044 - 2526 7517 / 2527 0992 / Fax: 044 25261264, E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

Extracts of Unaudited Financial Results for the Quarter And Half Year ended September 30, 2026.

(Rs. In Lakhs) Except EPS

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4,766.56	2,658.32	3,546.82	7,424.88	7,009.22	15,061.74
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,109.98
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	690.90	13.59	307.87	704.49	642.14	1,134.31
6	Equity Share Capital	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
7	Other Equity as per the Audited Balance Sheet of the previous year (excluding Revaluation Reserve)	-	-	-	8,489.62	6,757.16	7,249.32
8	Earnings Per Share Basic :	2.89	0.03	1.32	2.93	2.75	4.69
	Diluted :	2.89	0.03	1.32	2.93	2.75	4.69

Note: i). The above is an extract of the detailed Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of SEBI (LODR) Regulations, 2015. The detailed Results are available on the website of the Stock Exchanges and on the Company's website. The Results can also be accessed by scanning the below QR Code. ii).The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2026.

For BAFNA PHARMACEUTICALS LIMITED
SD/-
S Hemalatha
Whole Time Director
(DIN: 02714329)

Place: Chennai
Date: 11.11.2026

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340

Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038

Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Patresha
Managing Director
DIN: 01258918

Date: 12th November, 2026
Place: Pune

Navigate the market's twists and turns

Take a deep dive into a stock or sector with Compass in Business Standard, and gain insights into the trends, triggers, and shifts that could shape market movements ahead.

Business Standard Insight Out

RANE HOLDINGS LIMITED

Regd. Office : "MAITHRI", 132, Cathedral Road, Chennai - 600 086
visit us at: www.ranegroup.com CIN: L35999TN1936PLC002202

Extract of unaudited consolidated financial results for the quarter and half year ended September 30, 2026

Rs. Lakhs

S. No	Particulars	Quarter ended		Half Year ended	
		September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
		Unaudited	Unaudited	Unaudited	Unaudited
1.	Total Income	189,760	140,983	349,447	275,537
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	4,608	4,830	10,416	9,609
3.	Net Profit / (Loss) for the period before tax (after Exceptional items)	38,823	4,669	44,881	10,994
4.	Net Profit / (Loss) for the period after tax and Exceptional items	31,955	3,126	36,782	8,875
5.	Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax)]	32,094	2,562	36,756	8,183
6.	Equity Share Capital	1,428	1,428	1,428	1,428
7.	Earnings per share (EPS) (face value - Rs.10/- each) (not annualised for quarters and year to date periods)				
	Basic (in Rs.)	140.97	16.45	167.15	52.01
	Diluted (in Rs.)	140.32	16.45	166.76	52.01

1. The above Unaudited financial results were reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on November 12, 2026.
2. The full results are available on the website at the link - https://ranegroup.com/investors/rane-holdings-limited/?rhl-fin-3

QR Code :

For Rane Holdings Limited
L Ganesh
Chairman & Managing Director

Place : Chennai
Date : November 12, 2026

DECCAN CEMENTS LIMITED

CIN: L26942TG1979PLC002500

Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad, Telangana - 500 082.

Ph: 040-23310168, **Email**: secretarial@deccancements.com, **Website**: www.deccancements.com

Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026

(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42
2	Net Profit for the period (before Tax and Exceptional items)	(1872.28)	(722.00)	1246.57	(2594.29)	3293.14	2141.02	(1872.62)	(722.24)	1246.22	(2594.86)	3292.61	2139.71
3	Net Profit for the period before tax (after Exceptional items)	(1644.80)	(949.49)	1246.57	(2594.29)	3293.14	3425.09	(1645.14)	(949.72)	1246.22	(2594.86)	3292.61	3423.78
4	Net Profit for the period after tax (after Exceptional items)	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2859.12	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2857.81
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2909.06	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2907.75
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs. 5/- each)												
	1. Basic	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40
	2. Diluted	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40

Notes

a) The above Standalone and Consolidated results for the quarter ended and half year ended 30th September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12th November, 2026.

b) The above is an extract of the detailed format of Standalone and Consolidated financial results filed for the quarter ended and half year ended 30th September 2026 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd (www.nseindia.com) and also on the Company's website (www.deccancements.com).

for DECCAN CEMENTS LIMITED
Sd/-
P Parvathi
Chairperson and Managing Director
DIN:00016597

Place: Hyderabad
Date : November 12, 2026

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly follow-ing the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subse-quent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- NAION, a rare condition, affects one in 10,000 people annually
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-au mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghost-face, Chucky, characters from Five Nights at Freddy's 2 and Fi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a re-creation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-be acter conceived by its creator. OCs, take cosplay beyond rec-OC reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Pritee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

BAFNA PHARMACEUTICALS LIMITED

CIN: L24294TN1995PLC030698

Regd. Off: No.299, Thambu Chetty Street, Chennai-600 001, Tel: 044 - 2526 7517 / 2527 0992 / Fax: 044 25261264, E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

Extracts of Unaudited Financial Results for the Quarter And Half Year ended September 30, 2026.

(Rs. In Lakhs) Except EPS

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4,766.56	2,658.32	3,546.82	7,424.88	7,009.22	15,061.74
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,109.98
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	690.90	13.59	307.87	704.49	642.14	1,134.31
6	Equity Share Capital	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
7	Other Equity as per the Audited Balance Sheet of the previous year (excluding Revaluation Reserve)	-	-	-	8,489.62	6,757.16	7,249.32
8	Earnings Per Share Basic :	2.89	0.03	1.32	2.93	2.75	4.69
	Diluted :	2.89	0.03	1.32	2.93	2.75	4.69

Note: i). The above is an extract of the detailed Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of SEBI (LODR) Regulations, 2015. The detailed Results are available on the website of the Stock Exchanges and on the Company's website. The Results can also be accessed by scanning the below QR Code. **ii).** The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2026.

Place: Chennai
Date: 11.11.2026

For BAFNA PHARMACEUTICALS LIMITED
SD/-
S Hemalatha
Whole Time Director
(DIN: 02714329)

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340

Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038

Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

Date: 12th November, 2026
Place: Pune

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Patresha
Managing Director
DIN: 01258918

Navigate the market's twists and turns

Take a deep dive into a stock or sector with Compass in Business Standard, and gain insights into the trends, triggers, and shifts that could shape market movements ahead.

Business Standard Insight Out

RANE HOLDINGS LIMITED

Regd. Office : "MAITHRI", 132, Cathedral Road, Chennai - 600 086

visit us at: www.ranegroup.com CIN: L35999TN1936PLC002202

Extract of unaudited consolidated financial results for the quarter and half year ended September 30, 2026

Rs. Lakhs

S. No	Particulars	Quarter ended		Half Year ended	
		September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
		Unaudited	Unaudited	Unaudited	Unaudited
1.	Total Income	189,760	140,983	349,447	275,537
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	4,608	4,830	10,416	9,609
3.	Net Profit / (Loss) for the period before tax (after Exceptional items)	38,823	4,669	44,881	10,994
4.	Net Profit / (Loss) for the period after tax and Exceptional items	31,955	3,126	36,782	8,875
5.	Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax)]	32,094	2,562	36,756	8,183
6.	Equity Share Capital	1,428	1,428	1,428	1,428
7.	Earnings per share (EPS) (face value - Rs.10/- each) (not annualised for quarters and year to date periods)				
	Basic (in Rs.)	140.97	16.45	167.15	52.01
	Diluted (in Rs.)	140.32	16.45	166.76	52.01

1. The above Unaudited financial results were reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on November 12, 2026.
2. The full results are available on the website at the link - https://ranegroup.com/investors/rane-holdings-limited/?rhl-fin-3

QR Code :

Place : Chennai
Date : November 12, 2026

For Rane Holdings Limited
L Ganesh
Chairman & Managing Director

DECCAN CEMENTS LIMITED

CIN: L26942TG1979PLC002500

Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad, Telangana - 500 082.

Ph: 040-23310168, **Email**: secretarial@deccancements.com, **Website**: www.deccancements.com

Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026

(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42
2	Net Profit for the period (before Tax and Exceptional items)	(1872.28)	(722.00)	1246.57	(2594.29)	3293.14	2141.02	(1872.62)	(722.24)	1246.22	(2594.86)	3292.61	2139.71
3	Net Profit for the period before tax (after Exceptional items)	(1644.80)	(949.49)	1246.57	(2594.29)	3293.14	3425.09	(1645.14)	(949.72)	1246.22	(2594.86)	3292.61	3423.78
4	Net Profit for the period after tax (after Exceptional items)	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2859.12	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2857.81
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2909.06	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2907.75
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs. 5/- each)												
	1. Basic	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40
	2. Diluted	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40

Notes

a) The above Standalone and Consolidated results for the quarter ended and half year ended 30th September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12th November, 2026.

b) The above is an extract of the detailed format of Standalone and Consolidated financial results filed for the quarter ended and half year ended 30th September 2026 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd (www.nseindia.com) and also on the Company's website (www.deccancements.com).

Place: Hyderabad
Date : November 12, 2026

for **DECCAN CEMENTS LIMITED**
Sd/-
P Parvathi
Chairperson and Managing Director
DIN:00016597

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly follow-ing the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subse-quent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION
- NAION, a rare condition, affects one in 10,000 people annually
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-au mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghost-face, Chucky, characters from Five Nights at Freddy's 2 and Fi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a re-creation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-be acter conceived by its creator. Such original characters, or OCs, take cosplay beyond rec-OC reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Priitee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

BAFNA PHARMACEUTICALS LIMITED

CIN: L24294TN1995PLC030698

Regd. Off: No.299, Thambu Chetty Street, Chennai-600 001, Tel: 044 - 2526 7517 / 2527 0992 / Fax: 044 25261264, E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

Extracts of Unaudited Financial Results for the Quarter And Half Year ended September 30, 2026.

(Rs. In Lakhs) Except EPS

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4,766.56	2,658.32	3,546.82	7,424.88	7,009.22	15,061.74
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,109.98
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	690.90	13.59	307.87	704.49	642.14	1,134.31
6	Equity Share Capital	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
7	Other Equity as per the Audited Balance Sheet of the previous year (excluding Revaluation Reserve)	-	-	-	8,489.62	6,757.16	7,249.32
8	Earnings Per Share Basic :	2.89	0.03	1.32	2.93	2.75	4.69
	Diluted :	2.89	0.03	1.32	2.93	2.75	4.69

Note: i). The above is an extract of the detailed Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of SEBI (LODR) Regulations, 2015. The detailed Results are available on the website of the Stock Exchanges and on the Company's website. The Results can also be accessed by scanning the below QR Code. ii).The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2026.

For BAFNA PHARMACEUTICALS LIMITED
SD/-
S Hemalatha
Whole Time Director
(DIN: 02714329)

Place: Chennai
Date: 11.11.2026

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340

Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038

Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Palresha
Managing Director
DIN: 01258918

Date: 12th November, 2026
Place: Pune

Navigate the market's twists and turns

Take a deep dive into a stock or sector with Compass in Business Standard, and gain insights into the trends, triggers, and shifts that could shape market movements ahead.

Business Standard Insight Out

RANE HOLDINGS LIMITED

Regd. Office : "MAITHRI", 132, Cathedral Road, Chennai - 600 086
visit us at: www.ranegroup.com CIN: L35999TN1936PLC002202

Extract of unaudited consolidated financial results for the quarter and half year ended September 30, 2026

Rs. Lakhs

S. No	Particulars	Quarter ended		Half Year ended	
		September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
		Unaudited	Unaudited	Unaudited	Unaudited
1.	Total Income	189,760	140,983	349,447	275,537
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	4,608	4,830	10,416	9,609
3.	Net Profit / (Loss) for the period before tax (after Exceptional items)	38,823	4,669	44,881	10,994
4.	Net Profit / (Loss) for the period after tax and Exceptional items	31,955	3,126	36,782	8,875
5.	Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax)]	32,094	2,562	36,756	8,183
6.	Equity Share Capital	1,428	1,428	1,428	1,428
7.	Earnings per share (EPS) (face value - Rs.10/- each) (not annualised for quarters and year to date periods)				
	Basic (in Rs.)	140.97	16.45	167.15	52.01
	Diluted (in Rs.)	140.32	16.45	166.76	52.01

1. The above Unaudited financial results were reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on November 12, 2026.
2. The full results are available on the website at the link - https://ranegroup.com/investors/rane-holdings-limited/?rhl-fin-3

QR Code :

For Rane Holdings Limited
L Ganesh
Chairman & Managing Director

Place : Chennai
Date : November 12, 2026

DECCAN CEMENTS LIMITED

CIN: L26942TG1979PLC002500

Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad, Telangana - 500 082.

Ph: 040-23310168, **Email**: secretarial@deccancements.com, **Website**: www.deccancements.com

Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026

(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42
2	Net Profit for the period (before Tax and Exceptional items)	(1872.28)	(722.00)	1246.57	(2594.29)	3293.14	2141.02	(1872.62)	(722.24)	1246.22	(2594.86)	3292.61	2139.71
3	Net Profit for the period before tax (after Exceptional items)	(1644.80)	(949.49)	1246.57	(2594.29)	3293.14	3425.09	(1645.14)	(949.72)	1246.22	(2594.86)	3292.61	3423.78
4	Net Profit for the period after tax (after Exceptional items)	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2859.12	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2857.81
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2909.06	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2907.75
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs. 5/- each)												
	1. Basic	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40
	2. Diluted	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40

Notes

a) The above Standalone and Consolidated results for the quarter ended and half year ended 30th September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12th November, 2026.

b) The above is an extract of the detailed format of Standalone and Consolidated financial results filed for the quarter ended and half year ended 30th September 2026 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd (www.nseindia.com) and also on the Company's website (www.deccancements.com).

for DECCAN CEMENTS LIMITED
Sd/-
P Parvathi
Chairperson and Managing Director
DIN:00016597

Place: Hyderabad
Date : November 12, 2026

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly follow-ing the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subse-quent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION
- NAION, a rare condition, affects one in 10,000 people annually
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-au mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghost-face, Chucky, characters from Five Nights at Freddy's 2 and Fi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a re-creation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-be acter conceived by its creator. OCs, take cosplay beyond rec-OC reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Pritee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

BAFNA PHARMACEUTICALS LIMITED

CIN: L24294TN1995PLC030698

Regd. Off: No.299, Thambu Chetty Street, Chennai-600 001, Tel: 044 - 2526 7517 / 2527 0992 / Fax: 044 25261264, E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

Extracts of Unaudited Financial Results for the Quarter And Half Year ended September 30, 2026.

(Rs. In Lakhs) Except EPS

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4,766.56	2,658.32	3,546.82	7,424.88	7,009.22	15,061.74
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,109.98
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	690.90	13.59	307.87	704.49	642.14	1,134.31
6	Equity Share Capital	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
7	Other Equity as per the Audited Balance Sheet of the previous year (excluding Revaluation Reserve)	-	-	-	8,489.62	6,757.16	7,249.32
8	Earnings Per Share Basic :	2.89	0.03	1.32	2.93	2.75	4.69
	Diluted :	2.89	0.03	1.32	2.93	2.75	4.69

Note: i). The above is an extract of the detailed Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of SEBI (LODR) Regulations, 2015. The detailed Results are available on the website of the Stock Exchanges and on the Company's website. The Results can also be accessed by scanning the below QR Code. **ii).** The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2026.

Place: Chennai
Date: 11.11.2026

For BAFNA PHARMACEUTICALS LIMITED
SD/-
S Hemalatha
Whole Time Director
(DIN: 02714329)

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340

Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038

Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

Date: 12th November, 2026
Place: Pune

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Patresha
Managing Director
DIN: 01258918

Navigate the market's twists and turns

Take a deep dive into a stock or sector with Compass in Business Standard, and gain insights into the trends, triggers, and shifts that could shape market movements ahead.

Business Standard Insight Out

RANE HOLDINGS LIMITED

Regd. Office : "MAITHRI", 132, Cathedral Road, Chennai - 600 086

visit us at: www.ranegroup.com CIN: L35999TN1936PLC002202

Extract of unaudited consolidated financial results for the quarter and half year ended September 30, 2026

Rs. Lakhs

S. No	Particulars	Quarter ended		Half Year ended	
		September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
		Unaudited	Unaudited	Unaudited	Unaudited
1.	Total Income	189,760	140,983	349,447	275,537
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	4,608	4,830	10,416	9,609
3.	Net Profit / (Loss) for the period before tax (after Exceptional items)	38,823	4,669	44,881	10,994
4.	Net Profit / (Loss) for the period after tax and Exceptional items	31,955	3,126	36,782	8,875
5.	Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax)]	32,094	2,562	36,756	8,183
6.	Equity Share Capital	1,428	1,428	1,428	1,428
7.	Earnings per share (EPS) (face value - Rs.10/- each) (not annualised for quarters and year to date periods)				
	Basic (in Rs.)	140.97	16.45	167.15	52.01
	Diluted (in Rs.)	140.32	16.45	166.76	52.01

1. The above Unaudited financial results were reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on November 12, 2026.
2. The full results are available on the website at the link - https://ranegroup.com/investors/rane-holdings-limited/?rhl-fin-3

QR Code :

Place : Chennai
Date : November 12, 2026

For Rane Holdings Limited
L Ganesh
Chairman & Managing Director

DECCAN CEMENTS LIMITED

CIN: L26942TG1979PLC002500

Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad, Telangana - 500 082.

Ph: 040-23310168, **Email**: secretarial@deccancements.com, **Website**: www.deccancements.com

Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026

(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42
2	Net Profit for the period (before Tax and Exceptional items)	(1872.28)	(722.00)	1246.57	(2594.29)	3293.14	2141.02	(1872.62)	(722.24)	1246.22	(2594.86)	3292.61	2139.71
3	Net Profit for the period before tax (after Exceptional items)	(1644.80)	(949.49)	1246.57	(2594.29)	3293.14	3425.09	(1645.14)	(949.72)	1246.22	(2594.86)	3292.61	3423.78
4	Net Profit for the period after tax (after Exceptional items)	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2859.12	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2857.81
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2909.06	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2907.75
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs. 5/- each)												
	1. Basic	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40
	2. Diluted	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40

Notes

a) The above Standalone and Consolidated results for the quarter ended and half year ended 30th September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12th November, 2026.

b) The above is an extract of the detailed format of Standalone and Consolidated financial results filed for the quarter ended and half year ended 30th September 2026 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd (www.nseindia.com) and also on the Company's website (www.deccancements.com).

Place: Hyderabad
Date : November 12, 2026

for **DECCAN CEMENTS LIMITED**
Sd/-
P Parvathi
Chairperson and Managing Director
DIN:00016597

Docs caution against sudden withdrawal of GLP-1 drugs

ANJALI SINGH
Mumbai, 12 November

Patients taking popular weight loss and diabetes medications such as semaglutide and tirzepatide should not discontinue treatment indiscriminately. This advice follows a regulatory warning in the United Stateswa that links these drugs to a rare eye condition that can cause permanent loss of vision, doc-pe tors in India have said.

Acknowledging the seriousness of nonarteritic anterior ischaemic optic neuropathy (NAION), specialists said the absolute risk remains very lowab and must be weighed against the metabolic and cardiovascular benefits of these medica-lar tions. The caution follows a November 9 warning by the USNo Food and Drug Administration (USFDA), which directed manufacturers of glucagon-like peptide-1 (GLP-1) receptorlike agonists to update their product labels to include a potential increased risk of NAION.

The warning comes amid a global boom in GLP-1 medications, which generated an estimated $79 billion in sales in 2025, according to Morgan Stanley. In India, the market has expanded rapidly follow-ing the launch of newer obesity treatments and the entry of lower-cost generic semaglutide earlier this year.

According to Pharmarack data, the GLP-1 market reached ₹2,492 crore in annual sales as of September, with sales value growing 72 per cent year-on-year during the month. Eli Lilly's Mounjaro, meanwhile, recorded sales of ₹1,544 crore in the 12 months ended October, up 229 per cent from a year earlier.

"NAION is a serious condition that requires attention, but it does not mean that we should start indiscriminately taking patients off GLP-1 medications or recommend eye examinations for everybody using these drugs. It is a very rare side effect, with roughly one additional case per 10,000 patient-years," said Rajiv Kovil, a diabetes and obesity specialist at Zandra Healthcare.

He said the association had been under discussion for around three years, following research published in JAMA Ophthalmology and subsequent observational studies indicating a nearly twofold increase in the incidence of NAION among GLP-1 users.

"The benefits of GLP-1 drugs go far beyond blood sugar control and weight reduction. They offer considerable organ protection, including cardiovascular, kidney and liver-related benefits. Indis-li criminately withdrawing these drugs could lead to a worsening of other associated conditions."

NAION, sometimes described as an "eye stroke", occurs when blood supply to the front portion of the optic nerve is reduced.

It typically causes sudden, painless vision loss in one eye, often noticed upon waking. The resulting impairment can be permanent, and there is no reliably effective treatment to reverse the damage.

The USFDA's analysis of 126 randomised clinical trials found 6.4 cases of NAION per 100,000 person-years among GLP-1 users, compared with 3.8 cases among those receiving a placebo or other glucose-lowering medications.

The regulator's warning covers medicines including Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). However, the precise biological mechanism behind the possible association remains unclear.

Kovil said patients experiencing blurred vision or other visual disturbances should consult an ophthalmologist. If NAION is diagnosed, the decision on whether to discontinue treatment should be made after weighing the patient's overall health and the benefits and risks of continuing the medication.

He also said India's pharmacovigilance system had not recorded a single case of NAION associated with GLP-1 medications over the past one and a half years, despite their growing use in the country. Oral semaglutide, he added, had been available in India for nearly four and a half years without any reported signal of the condition.

Separately, Aparna Bhaskar, a bariatric and metabolic surgeon, said she had not encountered NAION among patients receiving GLP-1 medications in her clinical practice.

However, she cautioned that the absence of cases in an individual practice did not rule out the risk. With the use of these medications growing in India, awareness of potential compli-aw cations and continued monitoring were important, she said. ing

Kovil said there was no indication for everyone taking GLP-1 medications to undergo additional eye examinations specifically to screen for NAION. Patients with diabetes, however, should continue their recommended eye examinations to monitor for diabetic eye complications.

He also pointed to the FOCUS (Fluoxetine Or Control Under Supervision) clinical trial studying semaglutide and diabetic retinopathy. According to him, recruitment for the study had recently stopped. The findings are expected to provide further information when published.

Doctors also stressed the importance of medical supervision before and during treat-sion ment. Patients with a history of NAION or other significant optic nerve disorders should discussner them with their physicians before starting therapy. be



What experts say

- Decision to discontinue treatment should be made after considering patient's af overall health
- GLP-1 drugs offer significant metabolic, cardiovascular, kidney, and liver-related benefits
- The US FDA directed GLP-1 drug makers to update their product labels to include potential risks of NAION
- NAION, a rare condition, affects one in 10,000 people annually
- Patients with diabetes should continue their recommended eye examinations to monitor for eye complications

A frightfully good business as horror looks beyond the screen

AYUSHI SINGH
New Delhi, 12 November

A bird skull for a face, one wing entirely white, the other streaked with red and black, a Greek-style toga and a katana hanging at his side. Around him stood Ghostface, a yellow ani-sto matronic Chica, a red-haired doll and an assortment of bloodied, stitched-up figures. bl

Beyond the nightmares were a cobweb-covered red London bus, tarot readings, gaming arenas and stalls selling gothic jewellery, graphic tees, horror comics and fantasy fiction. Children queued for face painting and Halloween games, while inside a tent, paranormal investigators, storytellers, and filmmakers held sessions throughout the day. As evening fell, the open-air stage came alive with pop, hip-hop and electronic music.

For two days, October 31 and November 1, the NSIC Grounds in Okhla hosted the third edition of HorrorCon India. Beyond the spectacle, the ambition is to make horror the centrepiece of a live entertainment property, with its own audience, creators and com-au mercial partners.

Horror already features at larger pop-culture gatherings such as Comic Con. HorrorCon is betting that the genre can stand on its own, bringing together fans of films, games and anime, as well as paranormal investigators, independent filmmakers and storytellers. Its Horror Geek Zone hosted sessions on horror writing, independent filmmaking, paranormal investigations and more, drawing on the community built by Khooni Monday, the horror platform run by TMV (The Mad Virus), the company behind the convention.

The bet comes as India's live event business expands. The Ficci-EY 2026 report estimates that the organised segment grew 44 per cent in 2025 to ₹14,500 crore. Its survey found that 31 per cent of event management companies offered intellectual property (IP)-led events, up from 24 per cent, while 82 per cent expected demand for such properties to grow. For HorrorCon, the opportunity lies in turning a specific cultural interest into an event that audiences return to and brands invest in.

The cosplay floor reflected the community's range. Ghostface, Chucky, characters from Five Nights at Freddy's 2 and Pi Pyramid Head from Silent Hill appeared alongside Sukuna from Jujutsu Kaisen, zombies from The Last of Us 2 and a recreation of the possessed bed sequence from 1920. But one costume, the Avian Seraph, was not borrowed from an existing fictional world. Its bird-skull mask, asymmetrical wings, toga and katana belonged to an original char-be acter conceived by its creator. OCs, take cosplay beyond rec-OC reating established franchises, allowing fans to imagine identities and worlds of their own, with the possibility of develop-ing them into original IP.

The programme extended beyond horror, featuring hip-hop duo Seedhe Maut, girl group W.i.S.H. (World inka Stage Hai), MTV Hustle rappers Ansh4Sure and Parv, singer-songwriter Bharat Chauhan, and electronic acts Nkshtra and Noizx. The wider lineup offers brands multiple entry points into a community whose members identify with particular genres and fandoms.

For HELL Energy, that means product trials and brand recall among young consumers.re The brand returned for its third year at HorrorCon and itsye second as title sponsor, with a Halloween bar on the grounds.

"What matters to us is whether a young consumer experiences HELL energy drink, tries the range and remembers it," said Pritee Tamhankar, the brand's marketing head. The company tracks brand awareness and product sampling, both of which she said hadbo grown since it joined. Tamhankar sees horror as having moved "from the fringes into a genre with its own devoted following among GenZ", much as K-drama did. The association has also given the brand a platform for HELLoween.

PVR Inox Pictures is looking to turn horror fandom into cinema visits. It partnered HorrorCon to organise exclusive screenings across Delhi-National Capital Region, including Backrooms, Prime-time and Hokum, before joining the convention.

More on business-standard.com



Spine-chilling: Cosplay enthusiasts at the third edition of HorrorCon India 2026, held from October 31 to November 1, at Okhla's NSIC Exhibition Grounds

बैंक ऑफ महाराष्ट्र Bank of Maharashtra

8th Floor - A Wing, Downtown Center, Erandwane, Near Mhatre Bridge, Pune, Maharashtra - 411004

NOTICE INVITING TENDER (RFP)

Bank of Maharashtra invites sealed tender offers (Technical bid and Commercial bid) from eligible and reputed bidders / service providers for **"RFP 67/2026-27 for Supply, Installation, configuration, commissioning and Maintenance of Hardware Peripherals for five years."**

The detailed tender document is available on tender section of Bank's website : **https://www.bankofmaharashtra.bank.in** and **Govt. e-Market place (GeM) portal https://gem.gov.in/ w.e.f. 11.11.2026** with following details:

RFP Ref No.: RFP 67/2026-27

GeM Bid No.: GEM/2026/B/8246322

Due date for Bid submission: 26.11.2026 17.00 hrs.

Interested bidders may download the RFP document from above mentioned sites. All further updates related to tenders will also be available on **GeM Portal.** Bank reserves the right to cancel or reschedule the RFP process without assigning any reason.

Sd/-
Dy. General Manager,
Information Technology

Date: 12.11.2026

BAFNA PHARMACEUTICALS LIMITED

CIN: L24294TN1995PLC030698

Regd. Off: No.299, Thambu Chetty Street, Chennai-600 001, Tel: 044 - 2526 7517 / 2527 0992 / Fax: 044 25261264, E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

Extracts of Unaudited Financial Results for the Quarter And Half Year ended September 30, 2026.

(Rs. In Lakhs) Except EPS

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4,766.56	2,658.32	3,546.82	7,424.88	7,009.22	15,061.74
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,109.98
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	690.90	13.59	307.87	704.49	642.14	1,134.31
6	Equity Share Capital	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
7	Other Equity as per the Audited Balance Sheet of the previous year (excluding Revaluation Reserve)	-	-	-	8,489.62	6,757.16	7,249.32
8	Earnings Per Share Basic :	2.89	0.03	1.32	2.93	2.75	4.69
	Diluted :	2.89	0.03	1.32	2.93	2.75	4.69

Note: i). The above is an extract of the detailed Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of SEBI (LODR) Regulations, 2015. The detailed Results are available on the website of the Stock Exchanges and on the Company's website. The Results can also be accessed by scanning the below QR Code. **ii).** The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2026.

Place: Chennai
Date: 11.11.2026

For BAFNA PHARMACEUTICALS LIMITED
SD/-
S Hemalatha
Whole Time Director
(DIN: 02714329)

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340

Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038

Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

Date: 12th November, 2026
Place: Pune

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Patresha
Managing Director
DIN: 01258918

Navigate the market's twists and turns

Take a deep dive into a stock or sector with Compass in Business Standard, and gain insights into the trends, triggers, and shifts that could shape market movements ahead.

Business Standard Insight Out

RANE HOLDINGS LIMITED

Regd. Office : "MAITHRI", 132, Cathedral Road, Chennai - 600 086

visit us at: www.ranegroup.com CIN: L35999TN1936PLC002202

Extract of unaudited consolidated financial results for the quarter and half year ended September 30, 2026

Rs. Lakhs

S. No	Particulars	Quarter ended		Half Year ended	
		September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
		Unaudited	Unaudited	Unaudited	Unaudited
1.	Total Income	189,760	140,983	349,447	275,537
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	4,608	4,830	10,416	9,609
3.	Net Profit / (Loss) for the period before tax (after Exceptional items)	38,823	4,669	44,881	10,994
4.	Net Profit / (Loss) for the period after tax and Exceptional items	31,955	3,126	36,782	8,875
5.	Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax)]	32,094	2,562	36,756	8,183
6.	Equity Share Capital	1,428	1,428	1,428	1,428
7.	Earnings per share (EPS) (face value - Rs.10/- each) (not annualised for quarters and year to date periods)				
	Basic (in Rs.)	140.97	16.45	167.15	52.01
	Diluted (in Rs.)	140.32	16.45	166.76	52.01

1. The above Unaudited financial results were reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on November 12, 2026.
2. The full results are available on the website at the link - https://ranegroup.com/investors/rane-holdings-limited/?rhl-fin-3

QR Code :

Place : Chennai
Date : November 12, 2026

For Rane Holdings Limited
L Ganesh
Chairman & Managing Director

DECCAN CEMENTS LIMITED

CIN: L26942TG1979PLC002500

Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad, Telangana - 500 082.

Ph: 040-23310168, **Email**: secretarial@deccancements.com, **Website**: www.deccancements.com

Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026

(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42	22168.20	21933.84	14031.18	44102.04	29087.13	63561.42
2	Net Profit for the period (before Tax and Exceptional items)	(1872.28)	(722.00)	1246.57	(2594.29)	3293.14	2141.02	(1872.62)	(722.24)	1246.22	(2594.86)	3292.61	2139.71
3	Net Profit for the period before tax (after Exceptional items)	(1644.80)	(949.49)	1246.57	(2594.29)	3293.14	3425.09	(1645.14)	(949.72)	1246.22	(2594.86)	3292.61	3423.78
4	Net Profit for the period after tax (after Exceptional items)	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2859.12	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2857.81
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1520.78)	(738.68)	906.94	(2259.45)	2442.03	2909.06	(1521.04)	(738.85)	906.67	(2259.89)	2441.63	2907.75
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs. 5/- each)												
	1. Basic	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40
	2. Diluted	(10.11)	(5.24)	6.47	(15.35)	17.43	20.41	(10.11)	(5.24)	6.47	(15.35)	17.43	20.40

Notes

a) The above Standalone and Consolidated results for the quarter ended and half year ended 30th September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 12th November, 2026.

b) The above is an extract of the detailed format of Standalone and Consolidated financial results filed for the quarter ended and half year ended 30th September 2026 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd (www.nseindia.com) and also on the Company's website (www.deccancements.com).

Place: Hyderabad
Date : November 12, 2026

for **DECCAN CEMENTS LIMITED**
Sd/-
P Parvathi
Chairperson and Managing Director
DIN:00016597

THE RAMESHWARA JUTE MILLS LIMITED

CIN : L17119WB1935PLC046111
Regd.Office : 9/1, R. N. Mukherjee Road, Kolkata-700001
Telephone No. : 033-2262 4413
E-Mail : rjm.ho@rjm.co.in; Website : www.rameshwarajute.com

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / HALF YEAR ENDED ON 30.09.2026 APPROVED BY THE BOARD OF DIRECTORS ON 11.11.2026

(All amount in ₹ Lakh unless otherwise stated)

Sl. No.	Particulars	Three months ended 30.09.2026	Previous Three months ended 30.06.2026	Corresponding Three months ended in the previous year 30.09.2025	Year to date figures for the current period ended 30.09.2026	Year to date figures for the previous period ended 30.09.2025	Year to date figures for the current period ended 31.03.2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations(net)	13.24	8.86	16.03	22.10	20.58	27.67
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(81.26)	(68.65)	(55.28)	(149.91)	(116.15)	(253.46)
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(81.26)	(68.65)	(55.28)	(149.91)	(116.15)	(253.46)
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(67.96)	(87.15)	(55.28)	(155.11)	(116.15)	(253.50)
5	Total Comprehensive Income for the period [Comprehensive Profit and (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	8.66	237.82	(160.74)	246.48	(114.96)	(206.25)
6	Equity Share Capital	26.61	26.61	26.61	26.61	26.61	26.61
7	Reserve (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-			-	9,307.70
8	Earnings per equity share (of Rs.10 each) (not annualised) 1. Basic 2. Diluted	(25.54) (25.54)	(32.75) (32.75)	(20.78) (20.78)	(58.31) (58.31)	(43.66) (43.66)	(95.28) (95.28)

Notes :

a) The above is an extract of the detailed format of quarterly Financial Results filed with the Stock Exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015. The full format of the quarterly Financial Results are available on the website of the Calcutta Stock Exchange at www.cse-india.com and on company's website at :http://rameshwarajute.com/quarterly_results.php. The same can also be accessed by scanning the QR code provided below.

b) There are no Exceptional and /or Extraordinary items adjusted in the Statement of Unaudited Financial Results for the quarter / half year ended 30.09.2026 in accordance with the Companies (Indian Accounting Standards) Rules , 2015.

For **The Rameshwara Jute Mills Limited**
sd/-
R. P. Pansari
(Chairman)
DIN -00869222

Place : Kolkata
Date : 11.11.2026

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340
Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038
Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Palresha
Managing Director
DIN: 01258918

Date: 12th November, 2026
Place: Pune

E-AUCTION SALE NOTICE

METAL CLOSURES PVT. LTD. (IN LIQUIDATION)

Reg. Off.: 39/4B, 12TH KM, Kankapura Main Road, Bangalore, Karnataka - 560062

Under Insolvency and Bankruptcy Code, 2016, the properties / Assets owned by the Corporate debtor **M/s METAL CLOSURES PVT. LTD., having CIN: U34203KA1977PTC003254** which are forming part of Liquidation Estate of CD and located in Karnataka, are for sale by the Liquidator, as per terms contained in this notice and other terms mentioned in the detailed process document. The sale of properties will be done by the undersigned through the e-auction platform https://ibbi.baanknet.com/auction.

Lot No.	Asset Description and Location	Reserve Price (Rs.)	EMD (Rs.)	Incremental value Rs.	E-auction date & time
	Sale of Individual asset(Please read process document for other terms and conditions)				
1	Land and Building of 1 Acre 20 Guntas located at Sy.Nos. 39/4B , Kanakapura Road, Doddakallasandra Village, Uttarahalli Hobli, Bangalore South Taluk, Karnataka.	90.00 Crs.	9.00 Crs.	1.00 Cr	10.00 AM to 11.00 AM on 27.11.2026
Timeline	Inspection of Factory / assets	Upto 23rd November 2026, on specific days, with prior appointment with Liquidation team			
	EMD Remittance	Upto 24th November 2026			
	E-Auction	10.00 AM on 27.11.2026			

Few Terms and Condition of the E-auction are as under:

1) Prospective bidders shall submit an undertaking that they do not suffer from any ineligibility under section 29A of the Code to the extent applicable and that if found ineligible at any stage, the earnest money deposited shall be forfeited.
2) In case the highest bidder is found ineligible, the liquidator shall, with the approval of the committee declare the next highest bidder as the successful bidder.
3) There is an Eligibility criteria for Sl.No.1. Kindly refer to the process document for details.
4) Decision of CoC to declare the Successful Bidders shall be final and binding on all bidders.
5) The EMD of unsuccessful bidders shall be refunded within 15 days.
6) Bidding will be allowed only if EMD prescribed is remitted as per specified timeline.
7) The Registration charges, GST, and other applicable charges, if any, shall be paid extra by the successful bidders, to conclude the sale.
8) E-Auction will be conducted on **"AS IS WHERE IS", "AS IS WHAT IS" and "WHATEVER THERE IS BASIS" "NO RECOURSE WHATSOVER BASIS"** through approved E-auction Platform **https://ibbi.baanknet.com/auction**
9) The Complete E-Auction process document containing details of the Asset, online Declaration and Undertaking Form, other Terms and Conditions of online auction sale may be obtained from **https://ibbi.baanknet.com/auction.** Also, by writing to Liquidator in **mcpl.liquidation@gmail.com .**
10) This notice is issued in compliance with the provisions of Insolvency and Bankruptcy Code.

s/d
Smt.Ramanathan Bhuvaneshwari
Liquidator
IP Reg. No: IBBI/IPA-002/IP-N00306/2017-18/10864

Date: 12.11.2026
Place: Bengaluru

ARSS INFRASTRUCTURE PROJECTS LIMITED

Regd. Office : Plot No.: 38, Sector-A, Zone-D, Mancheswar Industrial Estate, Bhubaneswar, Odisha - 751010
Corp. Office : ARSS Mall, Plot no-40, Community Centre, Block-A,Paschim Vihar,Opp-Jwalaheri Market, New Delhi - 110063
E-mail : cs@arssgroup.in, Website: www.arssgroup.in, CIN: L14103OR2000PLC006230

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON SEPTEMBER 30, 2026

Key numbers of Financial Results (Rs. in Lakhs)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter ended			Half year ended		Year ended	Quarter ended			Half year ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
1.	Total Revenue from Operations	2,310.91	1,452.91	1,141.00	3,763.82	3,009.19	14,579.28	2,310.91	1,452.91	1,141.00	3,763.82	3,009.19	14,579.28
2.	Net Profit / (Loss) (before Tax, Exceptional and/or Extraordinary Items)	(896.58)	(1,093.12)	(415.96)	(1,989.70)	(11,932.88)	(11,847.24)	(897.87)	(1,094.13)	(417.55)	(1,991.99)	(11,938.43)	(11,853.54)
3.	Net Profit/(Loss) before Tax (after Exceptional and/or Extraordinary Items)	(896.58)	(1,093.12)	(322,734.60)	(1,989.70)	(334,251.50)	(355,260.30)	(896.47)	(1,087.46)	(322,702.72)	(1,983.92)	(334,221.51)	(355,119.73)
4.	Net Profit / (Loss) after Tax (after Exceptional and/or Extraordinary Items)	(806.96)	(1,095.64)	(322,770.03)	(1,902.60)	(334,322.51)	(355,498.04)	(806.85)	(1,089.98)	(322,738.15)	(1,896.82)	(334,292.52)	(355,357.47)
5.	Total Comprehensive Income [Comprising Profit / (Loss) after Tax and Other Comprehensive Income after tax]	(806.96)	(1,095.64)	(322,770.03)	(1,902.60)	(334,322.51)	(355,498.04)	(806.85)	(1,089.98)	(322,738.15)	(1,896.82)	(334,292.52)	(355,357.47)
6.	Equity Share Capital	9,011.85	9,011.85	1,511.85	9,011.85	1,511.85	9,011.85	9,011.85	9,011.85	1,511.85	9,011.85	1,511.85	9,011.85
7.	Earnings per share (of ₹10/- each) Basic & Diluted (Rs.)	(0.90)	(1.22)	(1,428.25)	(2.11)	(1,479.36)	(394.48)	(0.90)	(1.21)	(1,428.11)	(2.10)	(1,479.23)	(394.32)

Notes:

a) The above standalone & consolidated unaudited financial results of the Company for the quarter and half Year ended September 30, 2026 have been reviewed by the audit committee and approved by the Board of Directors of the Company at its meeting held on November 10, 2026. These results are being published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

b) The above is an extract of the detailed format of the Statement of Standalone and consolidated unaudited Financial Results for the quarter and half year ended September 30, 2026 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Standalone and consolidated Unaudited Financial Results for the quarter and half year ended on 30th September, 2026 are available on the website of the Stock Exchanges - **www.bseindia.com & www.nseindia.com** as well as on the website of the Company - **www.arssgroup.in.**

http://arssgroup.in/PDF/QuarterlyResult/Board%20Meeting%20Outcome%2030.09.2026.pdf

-Sd-
(Dipti Ranjan Patnaik)
Chairman cum Managing Director
DIN : 00600887

Date : 10th November, 2026
Place : Bhubaneswar

SIGMA ADVANCED SYSTEMS LIMITED

(FORMERLY MEGASOFT LIMITED)

CIN: L24100TN1999PLC042730

Registered Office: No.43/1 (# 129 to # 140), Prestige Palladium, 8th Floor, Greams Road, Nungambakkam, Chennai, 600006, Tamil Nadu, India **Corporate Office:** Survey No 1/1, Plot No 24/A, Hardware Park, Srisailam Road, Kancha Imarat, Raviryala Village, Maheswaram Mandal, Hyderabad, 501510 Telangana, India
Email: investors@sigmaadvsys.com https://sigmaadvsys.com

POSTAL BALLOT NOTICE AND REMOTE E-VOTING INFORMATION

NOTICE is hereby given that pursuant to the provisions of Sections 110 and 108 of the Companies Act, 2013 (the 'Act') read with Rules 22 and 20 of the Companies (Management and Administration) Rules, 2014 and amendments thereto, Secretarial Standard-2 on General Meetings (the 'SS-2'), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'SEBI Listing Regulations') including any statutory modification(s), clarification(s), substitution(s) or re-enactment(s) thereof for the time being in force, guidelines prescribed by the Ministry of Corporate Affairs (the 'MCA'), vide Circular No. 14/2020 dated April 8, 2020, Circular No. 20/2020 dated May 05, 2020, Circular No. 2/2022 dated May 05,2022, Circular No. 10/2022 and Circular No. 11/2022 dated December 28,2022, Circular No. 02/2021 dated January, 13, 2021 and General Circular No. 09/2023 dated September 25, 2023 and General Circular No. 09/2024 dated September 19, 2024 and No. 03/2025 dated September 22, 2025 read along with SEBI circular no. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated 3rd October, 2024 and other connected circulars issued from time to time in this regard (the 'MCA Circulars') and any other applicable law, rules and regulations (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force and as amended from time to time), the items as set out in this Notice are proposed for consideration by the Members of Sigma Advanced Systems Limited (the 'Company') and for approval by means of Postal Ballot by voting through electronic means ('remote e-voting') only.

Item	Description of the Resolution
1.	To consider and approve enhancement in overall Borrowing Limits of the Company.
2.	To consider and approve creation of security on assets of the Company.
3.	To consider and approve enhancement of limits for the purpose of Granting of Loan (s), making Investment(s) and Providing Guarantee(s)/ Security(ies) under section 186 of Companies Act, 2013.
4.	To approve the Appointment of Mr. Galla Jayadev (DIN:00143610), as an Independent Director (Non-Executive) of the Company for a Term of Five Consecutive years w.e.f November 06, 2026.
5.	To approve the Appointment of Ms. Urkavalan Jeya Santhi (DIN:11338879), as an Independent Women Director (Non-Executive) of the Company for a Term of Five Consecutive years w.e.f November 06, 2026.
6.	To approve the change in designation of Mr. Sunil Kumar Kalidindi (DIN: 02344343) from Whole-Time Director to Managing Director of the Company.
7.	To Consider and Approve the Proposal for Change in Designation of Mr. Kartheek Raju Chintalapati (DIN:02921819) from Non-Executive Director to Whole-Time Director (Executive, Promoter Category) of the Company for a term of five consecutive years w.e.f. November 06, 2026 and fix remuneration thereof.
8.	To consider & approve raising of funds by way of issuance of equity shares and/or any other eligible securities through a further public offer, preferential allotment, rights issue, private placement, qualified institutions placement, or any other permissible method or combination thereof, in accordance with the applicable laws.

In Compliance with the MCA circulars, the Company has completed the dispatch of Notice along with Explanatory Statement through an email on November 10th, 2026 to the members of the Company holding Equity Shares as on Friday, November 06th, 2026 ("Cut-Off Date"). Voting rights shall be reckoned on the paid-up value of Equity shares registered in the name of Members as on the Cut-Off date. A person who is not a member as on Cut-Off date to treat the Notice for information purpose only. Kindly note that in terms of the Applicable Laws, physical copy of the Postal Ballot Notice along with Postal Ballot form and pre-paid business reply envelope will not be sent to the Members. The Communication of the assent or dissent of the Members would take place through remote e-voting system only.

Members may note that Postal Ballot Notice is also available on the website of the Company at https://sigmaadvsys.com/investors-services/announcements/ and can also be accessed from the website of the stock exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com. The Notice is also available on the website of CDSL at www.evotingindia.com.

As required under section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, the Company has engaged the services of Central Depository Services (India) Limited to provide e-voting facility to the shareholders of the Company. Members holding shares in dematerialized form as on the cut off date i.e. Friday, November 06th, 2026, may cast their votes electronically on the business as set forth in the Postal Ballot through the electronic voting systems of NSDL/CDSL (remote e-voting). Members are hereby informed that:

a) The business set forth in the Postal Ballot Notice may be transacted through remote e-voting systems.
b) The remote e-voting shall commence on Wednesday, November 11th, 2026 (at 9.00 AM IST) and ends on Thursday, December 10th, 2026 (at 5.00 PM IST). Members may note that once the votes are cast on a resolution, the members shall not be allowed to change it subsequently.
c) The cut-off date for determining the eligibility to vote by remote e-voting shall be Friday, November 06th, 2026.
d) Remote e-voting module will be disabled after 5.00 PM IST on Thursday, December 10th, 2026.
e) In case of queries, Members may refer to the Frequently Asked Questions (FAQs) for Members and e-voting user manual for Members at the Downloads Section www.evotingindia.com or write an email to helpdesk.evoting@cdslindia.com. Members may also write to the Company at investors@sigmaadvsys.com E-mail ID or at the Corporate office address of the Company at Hyderabad i.e., Survey No 1/1 Plot No 24/A Hardware Park Srisailam Road Kancha Imarat, Raviryala Village Maheswaram Mandal, Hyderabad, Telangana, India, 501510.
f) The Board of Directors of the Company has appointed Mr. M. Damodaran, Managing Partner of M. Damodaran & Associates LLP, Practicing Company Secretaries, to act as Scrutinizer to scrutinize the e-voting process in a fair and transparent manner. The results declared along with the Scrutinizer's report shall be communicated to the stock exchanges and will also be displayed on the Company at https://sigmaadvsys.com within 2 working days of conclusion of e-voting period.

For Sigma Advanced Systems Limited
(Formerly Megasoft Limited)

Sd/-
Krishna Chaitanya Sadhu
Company Secretary & Compliance Officer

Date: November 10, 2026
Place: Hyderabad

SICAL LOGISTICS LIMITED

CIN: L51909TN1955PLC002431
Regd. Office: South India House, 73, Armenian Street, Chennai - 600 001, Tamil Nadu.
Telephone: +91-4466157071; Fax: +91-4466157017 E-mail: cs@pristinelogistics.com Website: www.sical.in

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

[Pursuant to Regulation 47[1][b] of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015]

(₹ in Lakhs, except per equity share data)

S.No.	Particulars	Quarter ended			Half year ended		Year ended
		30 Sept 2026 Unaudited	30 June 2026 Unaudited	30 Sept 2025 Unaudited	30 Sept 2026 Unaudited	30 Sept 2025 Unaudited	31 Mar 2026 Audited
1	Revenue from operations	10,546	13,258	8,981	23,804	18,735	38,568
2	Net Profit/(Loss) for the period [before Tax, Exceptional / Extra-ordinary items]	(1,067)	507	1,398	(560)	1,387	150
3	Net Profit/(Loss) for the period before tax [after Exceptional / Extra-ordinary Items]	(1,067)	2,248	1,398	1,181	1,387	5,709
4	Net profit/(Loss) for the period after tax [after Exceptional/Extra-ordinary Items]	(1,123)	2,121	1,305	998	1,002	4,916
5	Total comprehensive income/(Loss) for the period (comprising profit/(Loss) for the period after tax and other comprehensive income/expenses after tax) including share of profit from joint venture	(1,104)	2,124	1,311	1,020	1,012	5 4,973
6	Paid-up equity share capital (par value Rs. 10/- each, fully paid)	7,978	7,978	6,525	7,978	6,525	7,978
7	Reserves [excluding Revaluation Reserve] (as at)	-	-		-	-	5,151
8	Earnings per share (par value Rs.10/- each)						
	Basic [in Rs.]	(1.38)	2.86	2.01	1.28	1.55	6.54
	Diluted [in Rs.]	(1.38)	2.86	2.01	1.28	1.55	6.54

Notes:

(1) Unaudited financial results of Sical Logistics Limited (standalone information) :

(₹ in Lakhs)

S.No.	Particulars	Quarter ended			Half year ended		Year ended
		30 Sept 2026 Unaudited	30 June 2026 Unaudited	30 Sept 2025 Unaudited	30 Sept 2026 Unaudited	30 Sept 2025 Unaudited	31 Mar 2026 Audited
1.	Revenue from operations	4,780	7,108	3,663	11,888	8,063	16,477
2.	Profit/(Loss) before tax	(1,319)	1,835	994	516	363	3,956
3.	Total comprehensive income/(loss) for the period/year	(1,317)	1,835	994	519	363	3,960

2. The above is an extract of the detailed format of unaudited consolidated financial results for the quarter and half year ended 30th September 2026 filed with the Stock Exchanges under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, duly reviewed, approved and authenticated by the Board of Directors at their meeting held on November 11, 2026. The full format of the unaudited consolidated financial results for the quarter and half year ended 30th September 2026 are available on the websites of National Stock Exchange of India Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and on the Company's website www.sical.in/investers/results

For and on behalf of the Board of Directors
SICAL LOGISTICS LIMITED

Sd/-
Seshadri Rajappan
Whole-time Director
DIN: 00862481

Place : Chennai
Date : November 11, 2026

Dr.Reddy's

NOTICE OF LOSS OF SHARE CERTIFICATES

Notice is hereby given that the following Share Certificates issued by the Company are reported to have been lost or misplaced and the registered Shareholders/Claimants thereto have applied to the Company for the issue of duplicate share certificates.

S No.	Folio No.	Name of the Shareholder	Certificate No(s).	No. of Shares	Distinctive Nos. From - To
1	S01871*	Sunil Ramanlal Parekh	22281	200	77711772-77711971
2	S05182**	Sunil Ramanlal Parekh	192006	100	19593485-19593584
3	N00311*	Nisar Ahmed Hussain Wagle Shehnaz Raziya	17116	250	54365527-54365776
4	J00919**	Jayshree N Shah	131697	100	9693929-9694028
5	N00341**	Nisar Ahmed Hussain Wagle	26519-26520	75	1765541-1765615
		Shehnaz	77775	50	5681271-5681320
		Raziya	14204-14205	100	1255051-1255150

*Shares of Rs.5/- face value **Shares of Rs.10/- face value

The public is hereby cautioned against dealing in any manner with the above share certificates. Any person(s) who has/have any claim in respect of the said share certificate(s) should lodge claim(s) at the Company's **Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034** within 15 days of publication of this notice after which no claim(s) will be entertained and the Company will proceed to issue duplicate share certificate(s).

For Dr. Reddy's Laboratories Limited
K Randhir Singh
Company Secretary , Compliance Officer and Head - CSR

Place : Hyderabad
Date : 10-11-2026

DR. REDDY'S LABORATORIES LIMITED
Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034
CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900; Fax: 91 40 4900 2999
email: shares@drreddys.com; website:www.drreddys.com

BAFNA PHARMACEUTICALS LIMITED

CIN: L24294TN1995PLC030698
Regd. Off: No.299, Thambu Chetty Street, Chennai-600 001, Tel: 044 - 2526 7517 / 2527 0992 / Fax: 044 25261264, E-mail: info@bafnapharma.com, Website: www.bafnapharma.com

Extracts of Unaudited Financial Results for the Quarter And Half Year ended September 30, 2026.

(Rs. In Lakhs) Except EPS

S. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4,766.56	2,658.32	3,546.82	7,424.88	7,009.22	15,061.74
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,097.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	684.82	7.51	312.49	692.33	651.38	1,109.98
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	690.90	13.59	307.87	704.49	642.14	1,134.31
6	Equity Share Capital	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63	2,365.63
7	Other Equity as per the Audited Balance Sheet of the previous year (excluding Revaluation Reserve)	-	-	-	8,489.62	6,757.16	7,249.32
8	Earnings Per Share Basic :	2.89	0.03	1.32	2.93	2.75	4.69
	Diluted :	2.89	0.03	1.32	2.93	2.75	4.69

Note: i). The above is an extract of the detailed Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of SEBI (LODR) Regulations, 2015. The detailed Results are available on the website of the Stock Exchanges and on the Company's website. The Results can also be accessed by scanning the below QR Code. **ii).**The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 11, 2026.

Place: Chennai
Date: 11.11.2026

For BAFNA PHARMACEUTICALS LIMITED
SD/-
S Hemalatha
Whole Time Director
(DIN: 02714329)

NOTIFICATION

Name of the Applicant: AD Hydro Power Limited having its Head Office at Bhilwara Towers, A-12, Sector - Noida - 201 301, U.P.

(1) The applicant above named has filed a True-up Petition before Hon'ble Central Electricity Regulatory Commission, New Delhi for the approval of Tariff for its Transmission System for the period 2010-2014, 2014-2019 and 2019-2024 and MYT cum True up for the period 2019-2024.

(2) The details of the Transmission System are 220 kV D/C Prini-Nalagarh ADHPL Transmission System alongwith transmission bays.

(3) The beneficiary of the Transmission System are Northern India Region.

(4) The details of the Tariff based on True-up are as under:-

(Rs. In lacs)

2010-11	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17
4,383.43	4,224.69	6,047.92	5,921.86	6,047.09	5,815.64	5,551.58

(Rs. In lacs)

2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24
5,343.73	5,160.53	4,598.30	4,584.15	4,661.10	4,295.89	2,766.21

(5) The copy of the petition made for approval is posted on ADHPL's Website www.adhydropower.com.

(6) The suggestions & objections if any, on the proposal for determination of tariff contained in the application be filed by any person, including the beneficiary before the Secretary, Central Electricity Regulatory Commission, 6th, 7th & 8th Floors, Tower B, World Trade Centre, Nauroji Nagar, New Delhi 110 029 with a copy to the Petitioner Vice President (Commercial), AD Hydro Power Limited, Bhilwara Towers, A-12, Sector 1, Noida, U.P.

Place : Noida (U.P.)
Date : 11 November, 2026

Vice President (Commercial)

NOTICE

SUNDARAM MUTUAL — Sundaram Finance Group

RECORD DATE FOR INCOME DISTRIBUTION CUM CAPITAL WITHDRAWAL (IDCW)

NOTICE is hereby given that Sundaram Trustee Company Limited, the Trustee to Sundaram Mutual Fund, has declared Income Distribution cum capital withdrawal (IDCW) on the face value of Rs 10/- under the following schemes:

Scheme Name	Plan	Option	Record Date #	Amount of IDCW* (Rs. per unit)	NAV per unit as on November 11, 2026 (Rs.)
Sundaram Aggressive Hybrid Fund	Regular	Monthly IDCW	November 17, 2026	0.210	24.3473
	Direct	Monthly IDCW		0.330	38.3391
Sundaram Dynamic Asset Allocation Fund (Formerly known as Sundaram Balanced Advantage Fund)	Regular	Monthly IDCW		0.115	14.0520
	Direct	Monthly IDCW		0.140	17.5368

Or subsequent business day if the specified date is a non-business day.
* Income Distribution will be done/IDCW will be paid, net of tax deducted at source, as applicable.

Pursuant to the payment of IDCW, the NAV of the scheme will fall to the extent of payout and statutory levy, if applicable. The IDCW pay-out will be to the extent of above mentioned IDCW per unit or to the extent of available distributable surplus, as on the Record Date mentioned above, whichever is lower. Past performance may or may not be sustained in future. All unitholders under the IDCW Option of the above-mentioned schemes, whose name appears on the Register of Unitholders on the aforesaid Record Date, will be entitled to receive the IDCW.

Place: Chennai
Date: November 13, 2026

For **Sundaram Asset Management Company Limited ,**
R. Ajith Kumar,
Company Secretary & Compliance Officer

For more information please contact:
Sundaram Asset Management Company Ltd
(Investment Manager to Sundaram Mutual Fund)
CIN: U93090TN1996PLC034615

Corporate Office: 1st and 2nd Floor, Sundaram Towers, 46, Whites Road, Royapettah, Chennai-14.
Toll 1860 425 7237 (India) +91 40 2345 2215 (NRI)
www.sundarammutual.com
Regd. Office: No. 21, Patullos Road, Chennai 600 002.

Mutual Fund Investments are subject to market risks, read all scheme related documents carefully.

D S KULKARNI DEVELOPERS LIMITED

CIN: L45201PN1991PLC063340
Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038
Phone No.: 020-67166716 • **Email:** cs@solitaire.in • **Website:** www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.96
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,733.40	(122.94)	4.02	1,610.46	51.13	(36.45)	(152.19)	(275.13)
Equity Share Capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year					(13,879.12)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) :								
(a) Basic	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)
(b) Diluted	17.33	(1.23)	0.04	16.10	0.51	(0.36)	(1.52)	(2.75)

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly results are available on the Stock Exchange websites, i.e. www.bseindia.com, www.nseindia.com and the Company website www.dskcirp.com.

Date: 12th November, 2026
Place: Pune

For and On behalf of the Board of Directors of
D S Kulkarni Developers Limited
Bhushan Vilas Palresha
Managing Director
DIN: 01258918

— TENDER CARE — — Advertorial

SIGNING OF MOU BETWEEN GAIL (INDIA) LIMITED & KRISHAK BHARATI COOPERATIVE LIMITED FOR EXPLORING THE OPPORTUNITY TO SET UP A GAS-BASED FERTILIZER PROJECT IN THE STATE OF ANDHRA PRADESH

GAIL (India) Limited, India's flagship natural gas company signed a Memorandum of Understanding (MoU) with Krishak Bharati Cooperative Limited (KRIBHCO) to explore the opportunity of setting up a gas-based fertilizer project in the State of Andhra Pradesh.

The MoU was formally signed by Shri Sanjay Agarwal, ED (BD, Start-up & R&D), GAIL and Shri C.S.Azad, Executive Director (Technical), KRIBHCO, in the presence of Shri V Sudhakar Chowdary, Chairman, KRIBHCO, Shri S.S. Yadav, Managing Director, KRIBHCO and Shri R.K.Singhal, Director (Business Development), GAIL.

The urea production facility is envisaged to have a capacity of 1.27 Million Metric Tons Per Annum (MMTPA) in Mulapeta, Srikakulam district of Andhra Pradesh along GAIL's Srikakulam Angul Natural Gas Pipeline (SAPL). GAIL and KRIBHCO have agreed to join hands for implementation of the project through Joint Venture mode.

Speaking on the occasion, Shri V Sudhakar Chowdary, Chairman, KRIBHCO said: "The signing of this MoU marks the beginning of a strategic partnership between GAIL and KRIBHCO. I am confident that KRIBHCO's experience combined with GAIL's leadership position in natural gas sector would bring value to the proposed project for successful implementation."

Shri R.K. Singhal, Director (BD), GAIL stated that, "It represents a strategic integration of India's gas and fertiliser value chains and demonstrates GAIL's commitment to supporting sustainable industrial and agricultural growth."

OIL REPORTED 20% GROWTH IN CRUDE OIL PRODUCTION RESULTING TO 116% GROWTH IN STANDALONE PAT DURING Q2 FY27

Oil India Limited, the Maharatna CPSE of Govt. of India, declared its financial results for Q2FY27, in its 586th meeting of the Board of Directors held on 12th November 2026 at New Delhi.

The Company achieved a growth of 53% in Consolidated PAT at ₹ 2,521 crore in Q2 FY27 vis-à-vis ₹ 1,644 crore in Q2 FY26.



The consolidated PAT for the half year ended 30.09.2026 is ₹ 6,548 crore vis-à-vis ₹ 3,690 crore during corresponding previous half year, a growth of 77%.

The Company achieved a PAT of ₹ 2,259 Cr. in Q2FY27 vis-à-vis ₹ 1,044 Cr in Q2FY26, a growth of 116%, due to increase in crude oil production by 20% and crude oil price realisation by 35% from USD 68.19/bbl in Q2FY26 to USD 92.24/bbl in Q2FY27. The Company registered highest ever Standalone PAT for the half year ended 30.09.2026 at ₹ 5,130 crore as compared to ₹ 1,857 crore during corresponding previous half year, a growth of 176%.

The Board of Directors of the Company has recommended an Interim Dividend of ₹ 7.00/- per fully paid equity share of ₹10 each.

In its efforts towards ensuring Nation's Energy Security, the Company, continuing its sustained efforts, produced 1.021 MMT of crude oil from its matured and old oilfields in Q2FY27 vis-à-vis 0.848 MMT in Q2 FY26. OIL has achieved highest daily production of 11,300 MT (87,051 bbls) on 29.09.2026 of crude oil, which is highest daily production during the last decade.

BHEL EXPANDS ITS FOOTPRINT IN GRID STABILITY SOLUTIONS

Bharat Heavy Electricals Limited (BHEL) has achieved a significant milestone in the emerging Synchronous Condenser (SynCon) segment by securing two prestigious orders for installation of Synchronous Condensers at Barmer, Rajasthan and Kalyanpur, Gujarat.

These orders, received from Power Grid Corporation of India Limited (POWERGRID), comprise four Synchronous Condenser units, each rated at +300 MVAr / -200 MVAr, with BHEL's scope covering complete Design, Engineering, Manufacturing, Supply, Erection, Testing and Commissioning. This marks an important step towards BHEL's development and deployment of its first indigenously designed Synchronous Condenser solution, reflecting the company's sustained commitment to diversification into new areas, technological self-reliance and indigenous design, engineering and manufacturing capabilities, in line with the vision of 'Aatmanirbhar Bharat'.

GRSE STRENGTHENS FINANCIAL PERFORMANCE, REGISTERS IMPRESSIVE GROWTH IN Q2 & H1 FY27

Garden Reach Shipbuilders & Engineers Limited (GRSE), a Navratna Public Sector Undertaking under the Ministry of Defence, GOI has announced its financial results for the second quarter ended September 30th, 2026.

The revenue recorded during Q2 FY27 was Rs 1827 Cr, registering a growth of 9% over Q2 FY26. Similarly, the PAT has increased by 12% to Rs 232 Cr during the same period.

Commenting on the results, Cmde PR Hari, IN (Retd) Chairman and Managing Director, Garden Reach Shipbuilders & Engineers Limited said, "The Q2 & H1 FY27 results have been encouraging, with GRSE once again delivering a strong financial performance. The quarter marked several significant milestones for GRSE, including the launch of the second Next Generation Offshore Patrol Vessel 'Shruti' for the Indian Navy & an Ocean Research Vessel 'Sagar Manthan' for NCPOR, Ministry of Earth Sciences, and the Bhumi Pujan of three new major brownfield infrastructure projects in West Bengal."

HINDUSTAN COPPER H1 RESULTS SOAR BY 173%

The Board of Hindustan Copper Limited (HCL) in its meeting held in Kolkata has approved the Financial Results for the quarter and half year ended September, 2026.

First Half of FY 2026-27 : HCL has continued its strong performance with a 173% growth in Profit Before Tax (PBT) which has soared to Rs.1167.20 crore as against Rs.427.99 crore for the corresponding period of the last year (CPLY).

Profit After Tax (PAT) was Rs.872.15 crore as against Rs.320.30 crore for the CPLY, an increase of 172%.

Revenue from Operations was Rs.2111.74 crore as compared to Rs.1234.41 crore achieved in CPLY, registering a 71% increase. The EBITDA achieved was Rs.1268.00 crore.

The EBIDTA margin is a robust 60% as compared to 42% of CPLY.

Second Quarter of FY 2026-27 : PBT achieved is Rs.695.43 crore as compared to Rs.248.63 crore during the CPLY, registering an increase of 180%. Revenue from Operations is Rs.1175.24 crore as against Rs.718.04 crore of CPLY, clocking a growth of 64%. Profit After Tax (PAT) is Rs.519.54 crore vis-à-vis Rs.186.02 crore of CPLY, recording an increase of 179%. The Profit has been achieved through higher volume, metal prices duly supported by operational excellence and sustained productivity.

smc moneywise. be wise.

SMC GLOBAL SECURITIES LIMITED

CIN: L74899DL1994PLC063609
Regd. Office : 11/6B, Shanti Chamber, Pusa Road, New Delhi-110005. **Helpline Number: 011-66075200**

PUBLIC NOTICE

This Public Notice is issued on behalf of SMC Global Securities Limited (SMC), a duly registered stock broker with SEBI. Recently, it has come to our notice that a whole lot of community has been formed which impersonates SMC, claiming to be our management, employees to propagate their malicious agenda of scamming unaware customers through various social media platforms viz. WhatsApp groups/links, Telegram Channels, Facebook, Instagram accounts, etc. ("platforms") falsely impersonating as representatives of SMC or being affiliated with SMC. They are misusing the Name, Trademark & SEBI Regn No. of SMC and the name of Mr. Subhash Chandra Aggarwal, CMD, SMC Group, Mr. Mahesh C. Gupta Co-Founder & Vice CMD, SMC Group, Dr. D.K Aggarwal CMD-SMC Capitals Ltd., Mr. Ajay Garg - Director & CEO (SMC group), Mr. Himanshu Gupta Director & CEO (Moneywise Financial Services Pvt. Ltd.), Mrs. Reema Garg Director (Moneywise Finvest Ltd) & CHRO (SMC Group), Mrs. Shruti Aggarwal Director (SMC), Mr. Naveen ND Gupta, (Independent Director, SMC), Mr Govind Ram Choudhary (Independent Director, SMC), Mr. Nitin Murarka (Head - Research Analyst, SMC), & others in some investment and advisory audio/video clips by misusing technology and creating fraudulent WhatsApp & Telegram Groups with the intent of scamming. Please note, that SMC's management and its research experts' photos have been misused; they are not affiliated with any social media platform that provides financial advice with unprecedented returns. The Scammers are providing unregistered and unregulated fake websites, Fake SEBI letters, Fake Bank accounts, unregulated trading platforms & mobile applications which resemble or impersonate website/applications of SMC and luring to join/create institutional account to get guaranteed/high returns and deceiving public to invest the money, claiming to facilitate pre-IPO subscriptions with false promises of assured profits and offering illegal trading services etc. The details of fake Mobile Apps/WhatsApp group/Telegram channels/Facebook post/Instagram post etc. including but not limited, are as follows;

Fake Numbers

6367596917	6375329061	6376104258	6377209630	6377659121	6378099710	9358796739	9694290704
7046448072	7240082676	7414041307	7568553242	7597069326	7851061372	7649814703	9713747258
7976224556	8094086996	8233136790	8458984988	8503081698	8529194079	7649891383	9801771936
8619135565	8905166115	8905320275	8949689051	8955529482	8955988952	9479719103	9929542509
9057701633	9103908399	9131696150	9256532707	9351985395	9352532086	9694155256	9256774294
9360203343	9376318270	9376454959	9376459644	9376852269	9461618641	9462954832	8503968393
9509511514	9549152840	9571438753	9680460852	9680596454	9680784368	7014815015	8058150093
9783813744	9256176708	7665385569	9582061733	8442044307	9257274707	7877186268	7850812570
8529969309	8989570975	9352920776	8905942767	9166895636	9610292206	9461792104	9680589540
9461624540	9672546766	8000295895	9462968417	8154864049	9521683962	9772177585	9376178569
6367673337	9468731389	+1(347)424-2170	+1(808)989-6554	8824385515			

Fake Telegram/Facebook/Instagram Profiles

https://nitindipak.pages.dev/	https://t.me/%2Br9A5FN5bUhJhOTk1	https://www.facebook.com/profile.php?id=61593199151034
https://ca-nitin-academy-nrdu.onrender.com/	https://web.telegram.org/a/#-1003488770978	https://www.facebook.com/profile.php?id=61593181867405
https://www.facebook.com/oanvanhung.850037	https://t.me/+97Ni6EwvXzY0NWQ9	https://www.facebook.com/profile.php?id=61590314954612
https://www.facebook.com/share/1KxjURWhu8/	https://t.me/CA_NITIN_MURARKA	https://www.facebook.com/profile.php?id=61593794497359
https://www.facebook.com/profile.php?id=61592534198986	https://t.me/+WW74Dp2xTF4wNDQ1	https://www.facebook.com/profile.php?id=61593858213891
https://www.facebook.com/profile.php?id=61591753851243	https://t.me/+ytO6hJp4_coyNmI1	https://www.facebook.com/reel/1046470334653214
https://www.facebook.com/profile.php?id=61592289937353	https://t.me/+kn5T2FnZrQw5ZWM1	https://www.facebook.com/reel/1083670084188685
https://www.facebook.com/profile.php?id=61588762761865	https://t.me/+l24VPS9cnK4xMThl	https://www.facebook.com/reel/3360798190747462
https://www.facebook.com/profile.php?id=61593066952102	https://knowledgeadda4u.live/	https://www.facebook.com/reel/1116121577752762
https://t.me/+ZDxWPXWOPTJjNjA9	https://www.facebook.com/profile.php?id=61593319451174	https://t.me/STOCK_WITH_CA_NITIN_MURARKA_02
https://t.me/CommodityInsightswithVandana10	https://www.facebook.com/profile.php?id=61593420602290	https://canitinmurark.vercel.app/
https://t.me/indextradingsmcv	https://www.facebook.com/profile.php?id=61593256480371	https://murarka-04.vercel.app/
https://t.me/Zeebusiness_zee_business_nitin_m	https://www.facebook.com/profile.php?id=61590762212473	https://bespoke-seahorse-4be327.netlify.app/
https://t.me/+3nDhj5z3SfkzMDk1	https://www.facebook.com/profile.php?id=61592706428010	https://nitieducation.pages.dev
https://t.me/+kLX5E83UNoQ5NjRl	https://www.facebook.com/profile.php?id=61593390532893	https://www.facebook.com/reel/3761751807312133
https://t.me/+Np2XpxyVYVNkZmRl	https://www.facebook.com/profile.php?id=61593285147813	https://www.facebook.com/profile.php?id=61591649403911
https://t.me/+dX7U27F_Gf8wNWZl	https://www.facebook.com/profile.php?id=61591936914001	https://www.facebook.com/profile.php?id=100070708247626
https://prempankajog.live/	https://www.facebook.com/profile.php?id=61590829325140	https://www.facebook.com/profile.php?id=61592464538676
https://www.facebook.com/reel/1519344166108253	https://www.facebook.com/reel/1781796353248510	https://www.facebook.com/profile.php?id=61592692883521
https://www.instagram.com/canitinsir/	https://t.me/dghjjndse	https://www.facebook.com/profile.php?id=61591574309308
https://www.facebook.com/profile.php?id=61593699230404	https://t.me/nitin_murakar_offcial	https://www.facebook.com/profile.php?id=61593164756274
https://www.facebook.com/profile.php?id=61592243311380	https://t.me/trading_with_nitin_abhayy	https://www.facebook.com/profile.php?id=61589911681987
https://www.facebook.com/profile.php?id=61592447493421	https://t.me/zero_to_heroe	https://www.facebook.com/nitinmurarka09128272
https://www.facebook.com/profile.php?id=61592742333670	https://t.me/NITIN_MURARKA_42	https://www.facebook.com/profile.php?id=61592623979979
https://www.facebook.com/profile.php?id=61590780268252	https://t.me/+oDpDpImosU4xNDk9	https://www.facebook.com/profile.php?id=61592580141779
https://www.facebook.com/profile.php?id=61567891481893	https://t.me/+JBT2ZqM7YvQyZmJl	https://www.facebook.com/reel/2454738901677417
https://www.facebook.com/profile.php?id=61587825783207	https://t.me/+ohWyvxa8wENjZDJl	https://www.facebook.com/reel/2832890468342483
https://www.facebook.com/61593633483605/posts/122103109749454449	https://www.facebook.com/reel/1622255129305459	Nitin Murarka-@Nitin_Trader_30

This is to bring to the notice of general public that SMC Global Securities Ltd.:

- **Does Not Ask anybody to join WhatsApp groups for receiving recommendations on stocks IPOs leading to abnormally high, assured or guaranteed returns.**
- **Does Not Call/reach out to our customers from international numbers.**
- **Does Not Offer assured or guaranteed returns on any of our equity/equity linked products.**
- **Does Not Offer stocks at discounted prices.**
- **Does Not Assure allotment in IPOs.**

You may please refer this link (https://www.smctradeonline.com/beware-of-online-frauds) for our official list of websites / mobile applications / social media handles of SMC Global Securities Ltd. Further, if you have any questions or need more clarifications, please do not hesitate to contact us on our helpline number i.e. 011-66075200 (IVR Option No. 2 for Customer Support). Our Customer Service Executive would be happy to assist you in the best manner.

FAKE

रशियाकडून विक्रमी तेल खरेदी

भारत रशियन जीवाश्म इंधनाचा दुसरा सर्वांत मोठा खरेदीदार

▸ **दिल्ली, नवराष्ट्र न्यूज नेटवर्क.** भारताने ऑक्टोबरमध्ये रशियाकडून विक्रमी ६४० कोटी यूरो किमतीचे इंधन खरेदी केले. कच्च्या तेलाच्या आयातीत झालेली मोठी वाढ हे याचे मुख्य कारण होते. त्यामुळे, पाश्चात्य निर्बंध असूनही, रशियाच्या जीवाश्म इंधन निर्यातीतून मिळणारा महसूल डिसेंबर २०२२ नंतरच्या सर्वोच्च मासिक पातळीवर पोहोचण्यास मदत झाली. सेंटर फॉर रिसर्च ऑन एनर्जी ॲण्ड क्लीन एअरच्या मासिक विश्लेषणानुसार, ऑक्टोबर २०२६ मध्ये भारत रशियन जीवाश्म इंधनाचा दुसरा सर्वांत मोठा खरेदीदार होता. भारताने एकूण ६४० कोटी यूरो किमतीचे रशियन हायड्रोकार्बन्स आयात केले, जे जानेवारी २०२२ पासून उपलब्ध असलेल्या आकडेवारीनुसार आतापर्यंतचे सर्वाधिक मासिक आकडे आहेत. भारताच्या एकूण खरेदीपैकी ९१ टक्के वाटा कच्च्या तेलाचा होता, त्याचे मूल्य ५.८ अब्ज युरो होते. उर्वरित मासिक आयातीमध्ये कोळसा (३३.३ दशलक्ष युरो) आणि तेल उत्पादनांचा (२३.२ दशलक्ष युरो) समावेश होता. चीन हा रशियन जीवाश्म इंधनाचा सर्वांत मोठा जागतिक खरेदीदार राहिला आहे. शीर्ष पाच आयातकांकडून रशियाच्या निर्यात महसुलात त्याचा वाटा ५१ टक्के, म्हणजेच १०.७ अब्ज युरो होता. सीआरईएने म्हटले की, मागील महिन्याच्या तुलनेत ऑक्टोबर २०२६ मध्ये भारताची रशियन कच्च्या तेलाची आयात १० टक्क्यांनी वाढली. भारतातील तीन सर्वांत मोठ्या आयातदार रिफायनरींमध्ये रशियन कच्च्या तेलाची आयात वाढली. नायरा एनर्जीच्या वडीनार रिफायनरीमध्ये १२ टक्क्यांनी, रिलायन्स इंडस्ट्रीज लिमिटेडच्या जामनगर रिफायनरीमध्ये २२ टक्क्यांनी आणि इंडियन ऑइल कॉर्पोरेशन लिमिटेडच्या पारादीप रिफायनरीमध्ये २८ टक्क्यांनी. सीआरईएने म्हटले आहे की, या वाढीमुळे जामनगर रिफायनरी पुन्हा एकदा रशियन सागरी कच्च्या तेलाची सर्वांत मोठी आयातदार बनली आहे. ऑक्टोबर २०२६ मध्ये, युरोपियन युनियन रशियन जीवाश्म इंधनाचा तिसरा सर्वांत मोठा खरेदीदार होता. शीर्ष पाच आयातकांकडून रशियाच्या निर्यात महसुलात त्याचा वाटा ११ टक्के, म्हणजेच २.२ अब्ज युरो होता. रशियन कच्च्या तेलाचा वापर करणाऱ्या भारत, तुर्की आणि ब्रुनेईमधील तेल शुद्धीकरण कारखान्यांनी, फेब्रुवारी २०२२ मध्ये युक्रेनवर केलेल्या आक्रमणानंतर रशियावर निर्बंध लादणाऱ्या देशांना १.६ अब्ज युरो किमतीची तेल उत्पादने निर्यात केली. या उत्पादनांच्या निर्यातीच्या ठिकाणांमध्ये युरोपियन युनियन (१२० कोटी), ऑस्ट्रेलिया (२७.१ कोटी यूरो), अमेरिका (९.४ दशलक्ष युरो) आणि न्यूझीलंड (२.३ दशलक्ष युरो) यांचा समावेश आहे. यापैकी, असा अंदाज आहे की ३८.९ कोटी युरो किमतीची उत्पादने रशियन कच्च्या तेलाचा वापर करून तयार केली गेली. कच्च्या तेलाच्या निर्यातीतून मिळणारा महसूल २३ टक्क्यांनी वाढून प्रतिदिन ३५.२ कोटी युरो झाला.

तेलाची सरासरी किंमत १३ टक्क्यांनी वाढली



पाइपलाइनद्वारे होणाऱ्या कच्च्या तेलाच्या निर्यातीतून मिळणाऱ्या महसुलात सहा टक्क्यांनी वाढ झाली. रशियन युरल्स कच्च्या तेलाची सरासरी किंमत १३ टक्क्यांनी वाढून प्रति बॅरल १०१.७ डॉलर झाली. ऑक्टोबर २०२१ पासूनची ही सर्वोच्च मासिक सरासरी आहे आणि १ फेब्रुवारी २०२६ पासून लागू असलेल्या युरोपियन युनियन (ईयू) व युनायटेड किंगडमच्या (युके) प्रति बॅरल ४४.१ डॉलरच्या कमाल किंमत मर्यादेच्या दुप्पटीहून अधिक आहे. ऑक्टोबरमध्ये, युरल्स क्रूड ऑइलवर आंतरराष्ट्रीय बेंचमार्क, ब्रेंटच्या तुलनेत प्रति बॅरल २३ डॉलरची, म्हणजेच १९ टक्क्यांची सरासरी सूट होती. सप्टेंबरमध्ये, ही सूट प्रति बॅरल २४ डॉलर, म्हणजेच २१ टक्के होती.

'मोदीनॉमिक्स'मुळे भारताच्या आर्थिक परिवर्तनाला चालना



मंत्री राम मोहन नायडू यांचे प्रतिपादन

▸ **मुंबई, नवराष्ट्र न्यूज नेटवर्क.** भारताच्या गेल्या १२ वर्षांतील विकासाचे श्रेय 'मोदीनॉमिक्स'ला दिले. देश आज आपल्या आर्थिक प्रवासात एका निर्णायक टप्प्यावर उभा आहे, असे केंद्रीय नागरी हवाई वाहतूक मंत्री के. राम मोहन नायडू म्हणाले. आंध्र प्रदेशातील विशाखापट्टणम येथे दोन दिवसीय सीआयआय पार्टनरशिप समिटच्या ३१ व्या आवृत्तीच्या उद्घाटन सत्राला संबोधित करताना नायडू म्हणाले, जगाला राष्ट्रांमध्ये विश्वास, सरकार आणि उद्योगांमध्ये आत्मविश्वास आणि अनिश्चिततेचे संधीत रूपांतर करू शकणाऱ्या नेतृत्वाची गरज आहे. आज भारत आपल्या आर्थिक प्रवासात एका निर्णायक टप्प्यावर उभा आहे. जगातील सर्वांत मोठी तरुण लोकसंख्या, वेगाने विस्तारणारे डिजिटल वातावरण आणि उत्पादन, तंत्रज्ञान व नवोपक्रमातील वाढत्या क्षमतांमुळे भारत एक जागतिक शक्ती म्हणून उदयास येत आहे, असे नायडू म्हणाले. त्यांनी आज भारतात दिसणाऱ्या आत्मविश्वासाचे श्रेय पंतप्रधान नरेंद्र मोदी यांच्या 'मजबूत आणि निर्णायक' नेतृत्वाला दिले.

आता हल्दीराम आयपीओच्या तयारीत

आयपीओचा आकार १० हजार कोटी रुपये

▸ **दिल्ली, नवराष्ट्र न्यूज नेटवर्क.** हल्दीराम स्नॅक्स फूड्ने आपल्या प्रारंभिक सार्वजनिक ऑफरसाठी (आयपीओ) औपचारिकपणे प्रक्रिया सुरू केली. कंपनीने अनुपालन व्यवस्थापित करण्यासाठी आणि विविध विभागांमध्ये समन्वय साधण्यासाठी ईवायची आपले प्रकल्प व्यवस्थापन कार्यालय म्हणून नियुक्ती केली आहे.

सूत्रांचा हवाला देत दिलेल्या वृत्तानुसार, पारंपरिक भारतीय मिठाई आणि स्नॅक्स बनवणारी ही कंपनी २०२७ च्या अखेरपर्यंत सार्वजनिक सूचीकरणाचा विचार करत आहे. इश्यूचा आकार अंदाजे १० हजार कोटी रुपये असण्याचा अंदाज आहे, तर कंपनीचे मूल्यांकन १ लाख कोटी रुपयांपेक्षा जास्त असण्याचा अंदाज आहे. एका अधिकाऱ्याने सांगितले, पीएमओ टीमसोबत सार्वजनिक सूचीकरणाची प्रक्रिया औपचारिकपणे सुरू झाली आहे. व्यवसायाची वैविध्यपूर्ण आणि गुंतागुंतीची रचना पाहता, या प्रक्रियेला ६ ते १२ महिने किंवा त्याहून अधिक काळ लागू शकतो. प्रस्तावित आयपीओमध्ये विद्यमान भागधारकांकडून शेअर्सची विक्री आणि नवीन शेअर्सचे वाटप या दोन्हींचा समावेश असू शकतो. तथापि, या अहवालावर हल्दीराम स्नॅक्स फूड्चे सीईओ केके चुटानी किंवा ईवाय यांच्याकडून अद्याप कुठलीही अधिकृत प्रतिक्रिया आलेली नाही.

Short News

९.८९ लाख कोटींच्या ३०३ गुंतवणुका

विशाखापट्टणम. आंध्र प्रदेशचे मुख्यमंत्री एन. चंद्रबाबू नायडू यांनी राज्यात ९.८९ लाख कोटी रुपयांच्या ३०३ सामंजस्य करारांवर स्वाक्षरी केली जाईल, अशी घोषणा केली. दोन दिवसीय सीआयआय भागीदारी शिखर परिषदेत ही घोषणा केली. शिखर परिषदेच्या उद्घाटन सत्राला संबोधित करताना नायडू यांनी उद्योजकांना गुंतवणुकीचे प्रस्ताव घेऊन पुढे येण्याचे आणि राज्य सरकारसोबत सामंजस्य करारांवर स्वाक्षरी करण्याचे आवाहन केले.

शेअर

बीएसई	८१,९११.०१ (▲३१.६१)
निफ्टी	२५,२९९.३५ (▲४४.३०)
सोने स्टँडर्ड (१० ग्रॅम)	
सोने मुंबई	१,३८,०६४(▼)
सोने जळगाव	१,३८,०६४(▼)
चांदी (प्रतिकिग्रॅ)	
चांदी मुंबई	१,८१,१६२(▼)
चांदी जळगाव	१,८१,१६२(▼)
₹/डॉलर (प्रति डॉलर)	९४.०६
कच्चे तेल (प्रति बॅरल)	९३.५८

प्रत्यक्ष करसंकलनात ११.७६ टक्क्यांची वाढ

▸ **दिल्ली, नवराष्ट्र न्यूज नेटवर्क.** चालू आर्थिक वर्षात १ एप्रिल ते १० नोव्हेंबर दरम्यान निव्वळ प्रत्यक्ष कर संकलन ११.७६ टक्क्यांनी वाढून सुमारे १४.४२ लाख कोटी रुपयांवर पोहोचले. बुधवारी प्रसिद्ध झालेल्या सरकारी आकडेवारीनुसार हे चालू आर्थिक वर्षाच्या उद्दिष्टाच्या ५३ टक्के आहे. या कालावधीत, निव्वळ कॉर्पोरेट कर संकलन १८ टक्क्यांनी वाढून ६.३२ लाख कोटी रुपयांवर पोहोचले. वैयक्तिक करदाते, कंपन्या आणि हिंदू अविभक्त कुटुंबांकडून होणारे निव्वळ गैर-कॉर्पोरेट कर संकलन ५.३ टक्क्यांनी वाढून सुमारे ७.५६ लाख कोटी रुपयांवर पोहोचले. २०२६-२७ या आर्थिक वर्षात १० नोव्हेंबरपर्यंत प्रतिभूती व्यवहार करातून (एसटीटी) होणारे संकलन ५२ टक्क्यांनी वाढून ५४,०७८ कोटी रुपयांवर पोहोचले. या कालावधीत करदात्यांना देण्यात आलेला परतावा मागील वर्षाच्या तुलनेत २६ टक्क्यांनी वाढून ३.०८ लाख कोटी रुपयांवर पोहोचला आहे. एकूण प्रत्यक्ष कर संकलन १४ टक्क्यांनी वाढून १७.५० लाख कोटी रुपये झाले आहे. यामध्ये ८.०१ लाख कोटींचे एकूण कॉर्पोरेट कर संकलन आणि ८.९४ लाख कोटी रुपयांच्या गैर-कॉर्पोरेट कर संकलनाचा समावेश आहे. सरकारने चालू आर्थिक वर्षात प्रत्यक्ष करांमधून २६.९७ लाख कोटी रुपये गोळा करण्याचे लक्ष्य ठेवले आहे. २०२५-२६ या आर्थिक वर्षात मिळवलेल्या २३.४० लाख कोटी रुपयांच्या तुलनेत ही १५ टक्के वाढ आहे. सरकारने आतापर्यंत या लक्ष्यापैकी अंदाजे ५३ टक्के, म्हणजेच १४.४२ लाख कोटी रुपये गोळा केले आहेत.



१४.४२ लाख कोटी रुपयांवर पोहोचले

सर्फ, रिन, व्हीलच्या किमतीत ११% वाढ

▸ **दिल्ली, नवराष्ट्र न्यूज नेटवर्क.** हिंदुस्तान युनिलिव्हर लिमिटेडने वाढत्या खर्चाचा दबाव आणि नफ्याचे प्रमाण टिकवून ठेवण्याच्या प्रयत्नांमुळे आपल्या घरगुती उत्पादनांच्या श्रेणीतील सर्फ एक्सेल, रिन आणि व्हील या लोकप्रिय डिटर्जंट ब्रँड्ह अनेक उत्पादनांच्या कमाल किरकोळ किमतीत ११ टक्क्यांपर्यंत वाढ केली. एचयूएलचे व्यवस्थापकीय संचालक प्रिया नायर यांनी सांगितले की, कंपनी कच्च्या मालाच्या किमतीतील चढ-उतारानुसार विचारपूर्वक किमती वाढवत राहील.

Nippon India Mutual Fund

Mutual Fund Investor Awareness Program

To increase awareness about Mutual Funds, we conduct Investor Awareness Programmes (IAPs) across the country. The schedule of upcoming IAPs is as mentioned below

Date	Time	Location
13 November, 2026	6:00 PM	Satara

Venue: The Black Pearl Resto, Uttekar Nagar Sadar Bazar, Satara 415001

Name : Prathmesh Chavan | Mobile : 9370636029

Nippon Life India Asset Management Limited | CIN : L65910MH1995PLC220793

Mutual Fund Investments are subject to market risks, read all scheme related documents carefully.

जाहीर नोटीस

नमाद लोकांस या जाहीर नोटीसीने कळविण्यात येते की, तुकडी पुणे पेठ/कुरकुंडी तालुका हवेली सर्वेक्षण पुणे महानगरपालिकेचे हद्दीतील गाव **खोडे पाषी**, येथील सर्वे नंबर ६४ हिस्सा क्र. २//१ यामी एकूण क्षेत्र ०० हेक्टर ७५.४० आर या जमिन मिळकतीपैकी क्षेत्र ०० हे ०२ आर ही जमिन मिळकत यामी खालीलप्रमाणे-

पूर्वेस : श्री जगदाळे यांची मिळकत — दक्षिणेस : श्री पोमेकर यांची मिळकत
पश्चिमेस : श्री भोईरे यांची मिळकत — उत्तरेस : सातबारे २० फूटी रस्ता

वरील्प्रमाणे खालील मिळकतीचे विकसन मालक **श्री. किरण विजेंद्र शिंदे** व **श्री. विजेंद्र ओमप्रकाश शिंदे** रा. पुणे यांनी सदरची मिळकत आमचे अशिलांना फायनलमुळ खरेदी देण्याचे मान्य व कबूल केला आमचे अशिलांकडून विसारापोटी रक्कम मिळालेली आहे. सदरची मिळकत निर्बोध व मिरासदारी व बोजाविरहित असल्याची खात्री व भरवसा त्यांनी आमचे अशिलांना दिलेला आहे. तरी सदर मिळकतीवर इतर कोणाचाही गहाण, दान, बक्षीस, लीज, लीन, साका, वहिवाट, करार-मदार, पोटगी, माहेरचा हक्क कुलमुखत्यारपत्र वारे वा अन्य कोणत्याही स्वरूपाचा हक्क व अधिकार असल्यास संबंधितांनी सदर नोटिसीचे प्रसिध्दीपासून सात दिवसाचे आत आमची कागदपत्रांसहित व पुराव्यानिशी खाली पत्त्यावर खाली व लेखी हरकत नोंदवावी. मुदतीत कोणीही कोणतीही हरकत व म्हणणे सादर न केल्यास सदरची मिळकत विर्बोध, निर्वोदकी, व बोजाविरीत आहे व त्या कोणाचा हक्क व अधिकार नाही, त्यांनी तो बाणीवर्तुकीव सोडून दिला आहे असे समजून आमचे अशिल सदर मिळकतीचा खरेदीचा पुढील व्यवहार पूर्ण करतील त्यानंतर कोणत्याही कोणत्याही स्वरूपाची एखल पैसली ग्राह्य राहो. याची नोंद घ्यावी.

कराव्हे ही जाहीर नोटीस.

पुणे, दि. ११/११/२०२६

सही/-
निलेश मोहन मांदरे, ॲडव्होकेट
११, शिवकेसरी गव्हर्नर, मारली मंदिरासमोर, पुणे - ४०. मो. नंबर ८८८२११११९८

रब्बीसाठी खत अनुदानाला मंजुरी



▸ **दिल्ली, नवराष्ट्र ब्यूरो.** रब्बी हंगाम २०२६-२७ साठी फॉस्फेटिक आणि पोटॅशिक (पी अँड के) खतांवरील पोषक तत्त्वाधारित अनुदानाच्या (एनबीएस) दरांना केंद्रीय मंत्रिमंडळाने मंजुरी दिली आहे. पंतप्रधान नरेंद्र मोदी यांच्या अध्यक्षतेखाली झालेल्या मंत्रिमंडळ बैठकीत हा निर्णय घेण्यात आला. या हंगामासाठी केंद्र सरकारने सुमारे ६२ हजार ३७० कोटी २ लाख रुपयांच्या अर्थसंकल्पीय तरतुदीचा अंदाज व्यक्त केला आहे. मागील रब्बी हंगामातील ३७ हजार ९५२ कोटी २९ लाख रुपयांच्या तुलनेत यंदा अनुदानाच्या तरतुदीत तब्बल २४ हजार ४१७ कोटी ७३ लाख रुपयांची वाढ करण्यात आली आहे.

केंद्र सरकारच्या या निर्णयामुळे शेतकऱ्यांना डीएपी, एनपीकेएससह विविध प्रकारची खते परवडणाऱ्या आणि रास्त दरात उपलब्ध होण्यास मदत होणार आहे. आंतरराष्ट्रीय बाजारपेठेत खतांच्या तसेच त्यांच्या उत्पादनासाठी लागणाऱ्या कच्च्या मालाच्या किमतींमध्ये झालेल्या चढ-उतारांचा विचार करून अनुदानाचे दर निश्चित करण्यात आले आहेत.

निवडणुक निर्णय अधिकारी,
सोलापूर जिल्हा देखरेख सहकारी संस्था मर्या., सोलापूर.
संचालक मंडळ निवडणूक सन २०२६-२७ ते सन २०३१-३२ साठीची निवडणूक

जाहीर प्रकटन

सोलापूर जिल्हा देखरेख सहकारी संस्था मर्या., सोलापूर या संस्थेची संचालक मंडळ निवडणूक सन २०२६-२७ ते सन २०३१-३२ साठीच्या निवडणूक कार्यक्रमातील महत्वाचे टप्पे खालीलप्रमाणे आहेत.

नामनिर्देशन पत्र दाखल करण्याची तारीख व वेळ	नामनिर्देशन पत्राची छाननी दिनांक व वेळ	नामनिर्देशन पत्र मागे घेण्याची दिनांक व वेळ	आवश्यक असल्यास मतदान घेण्याची तारीख व वेळ	मतमोजणी ज्या तारखेस घेण्यात येईल ती तारीख
दि.१३/११/२०२६ ते दि.१९/११/२०२६ सकाळी ११.०० ते दु. ३.०० पर्यंत	दि.२०/११/२०२६ सकाळी ११.०० वा. पासून	दि. २३/११/२०२६ ते दि.०७/१२/२०२६ सकाळी ११.०० ते दु. ३.०० पर्यंत	दि.२०/१२/२०२६ सकाळी ८.०० ते सायं.४.०० पर्यंत	दि.२१/१२/२०२६ रोजी सकाळी ८.०० वाजलेपासून

टिप :- सविस्तर संचालक मंडळ निवडणूक कार्यक्रम देखरेख संस्थेचे कार्यालय, निवडणूक निर्णय अधिकारी व जिल्हा सहकारी निवडणूक अधिकारी यांच्या कार्यालयातील नोटीस बोर्डावर प्रसिध्द करण्यात आलेला आहे.

स्थळ : सोलापूर.
दिनांक : १३/११/२०२६

सही/-
(मुकुंद पवार)
निवडणूक निर्णय अधिकारी,
सोलापूर जिल्हा देखरेख सहकारी संस्था मर्या., सोलापूर तथा
जिल्हा उपनिबंधक, सहकारी संस्था, सोलापूर.

महाराष्ट्र शासन
सार्वजनिक बांधकाम विभाग
कार्यकारी अभियंता (विद्युत) विभाग, सोलापूर यांचे कार्यालय
९१६. सिव्हिल लाईन राष्ट्रीय महामार्ग वसाहत, सोलापूर- ४१३००३

जावक क्र.का.अ./सोविवि/निवि/१९२८/२०२६ दिनांक : ०२/११/२०२६	दूरध्वनी क्रमांक-: (०२१७) २३१२८९४ Email ID - cisolapur.ce@gmail.com elsolapur.ee@mahapwd.gov.in

ई निविदा सुचना क्र. ०७/२०२६ २०२७

कार्यकारी अभियंता सार्वजनिक बांधकाम सोलापूर विद्युत विभाग सोलापूर हे B -1 (Percentage Rate) नमुन्यातील निविदा ई - निविदा प्रणाली द्वारे ऑनलाइन मागवित असून कंत्राटदाराचे पात्रतेच्या अटोसंबंधीची माहिती निविदेत नमूद करण्यात आली आहे. निविदा कागदपत्रे शासनाच्या www.mahatenders.gov.in या संकेतस्थळावरून डाउनलोड करण्यात यावी तसेच निविदा स्विकारण्याचा अथवा नाकारण्याचा अधिकार निम्नस्वाक्षरीकारांनी राखून ठेवला आहे. अट असलेली निविदा स्विकारली जाणार नाही.

कामाचे नाव :- Estimate No. : 131004 of 2026 2027 Providing CCTV Surveillance System and Decorative Lighting System for external wall of Temple complex at Shri.Siddheshwar Temple, Solapur, Dist.- Solapur
(Amount Put to Tender : 1,55, 99,411/-)

१. निविदा उपलब्ध कालावधी : दिनांक १३.११.२०२६ स. ११.०० ते दिनांक २०.११.२०२६ रोजी १७.३० वा. पर्यंत
२. निविदा पुर्व बैठक व स्थळ : दि. १७.११.२०२६ रोजी १२.३० वा. मा. अधीक्षक अभियंता (विद्युत) पुणे प्रादेशिक विद्युत मंडळ, सा.बां. विभाग पुणे यांचे कार्यालय, शिवकिर्ती शासकीय वसाहत, सदनिका जी २/३ व जी- १०, घोरपडी, पुणे- ४११००१ **(व्हिडीओ कॉन्फरन्सद्वारे)**
(दि. १६.११.२०२६ रोजी १७ वा. पर्यंत निविदाकारांनी आपल्या शंका elsolapur.ee@mahapwd.gov.in या ई-मेल वर पाठविण्यात याव्यात.)
३. ई निविदा उघडणे : दिनांक २३.११.२०२६ रोजी अधीक्षक अभियंता (विद्युत) पुणे प्रादेशिक विद्युत मंडळ, सा.बां. विभाग पुणे यांचे कार्यालय, शिवकिर्ती शासकीय वसाहत, सदनिका जी २/३, व जी-१०, घोरपडी, पुणे-४११००१

खालील संकेतस्थळावर ई - निविदेची सर्व माहिती उपलब्ध आहे.
www.mahatenders.gov.in
सदर निविदा सुचनेमध्ये काही बदल होत असल्यास वरील वेबसाईटवर कळविण्यात येईल.

सही/-
(श्री.सु.गुजरे)
कार्यकारी अभियंता
सा.बां. सोलापूर विद्युत विभाग, सोलापूर

DGIPR 2026-27/3740

महाराष्ट्र शासन
नगर विकास विभाग
सहसंचालक, नगर रचना, पुणे विभाग, पुणे यांचे कार्यालय २१२, दुसरा मजला, नविन प्रशासकिय इमारत, विधान भवनासमोर, पुणे - ४११ ००१.
सूचना
महाराष्ट्र प्रादेशिक नियोजन व नगर रचना अधिनियम, १९६६

सुचना क्र.प्रा.यो.पुणे/मौ.मंगरूळ व मौ. नवलाख उंबरे, ता.मावळ/ग.नं.३० पै व इतर /कलम २०(३)/ सहसंपुवि/१५७५ दि.०३.११.२०२६

ज्याअर्थी, महाराष्ट्र प्रादेशिक नियोजन व नगर रचना अधिनियम, १९६६ (यापुढे ज्यास "उक्त अधिनियम" असे संबोधले आहे), मधील तरतूदीनुसार पुणे क्षेत्राची प्रादेशिक योजना (यापुढे ज्यास "उक्त प्रादेशिक योजना" असे संबोधले आहे) शासनाने दि. २५/११/१९९७ मंजूर केली असून, ती दि.१०/०२/१९९८ पासून अंमलात आलेली आहे;

आणि ज्याअर्थी, उक्त प्रादेशिक योजनेनुसार प्रस्तावाखालील एकूण क्षेत्र - २३.१७५८ हे. आर. पैकी १) मौजे मंगरूळ, ता. मावळ, जि. पुणे येथील,

अ) गट नं. ३०पै.,३९पै, ४०पै मधील ४.११९२ हे. आर क्षेत्र भागशः शेती तथा ना विकास विभागातून औद्योगिक विभागात समाविष्ट करणेबाबत;

ब) गट नं. ३०पै.,३९पै, ४०, ४१ पै., ४६ पै.,४८,४९/१ पै.,४९/२ पै. मधील १५.९६४२ हे. आर वनीकरण विभागातून शेती विभागात व शेती विभागातून औद्योगिक विभागात समाविष्ट करणेबाबत;

२) मौजे नवलाख उंबरे, ता. मावळ, जि. पुणे येथील गट नं. ४५० पै मधील ३.०९२४ हे. आर. क्षेत्र वनीकरण विभागातून शेती विभागात व शेती विभागातून औद्योगिक विभागात समाविष्ट करणेबाबत, मे. आर. एम. के. स्पेसेस तर्फे श्री. रामदास महादेव काकडे व इतर, यांनी दि.२७.११.२०२५ रोजी या कार्यालयास विनंती केलेली आहे;

आणि ज्याअर्थी, राज्यात मंजूर असलेल्या प्रादेशिक योजनांमध्ये उक्त अधिनियमाचे कलम २० अन्वये वेळोवेळी कराव्या लागणाऱ्या जमीन वापराच्या फेरबदला संदर्भाने करावयाच्या कार्यपध्दतीबाबत उक्त अधिनियमाचे कलम १५४ अन्वये शासन निर्णय क्र. टिपीएस-१८१५/ प्र.क्र.४९ / १५ / नवि-१३, दि.०६.०५.२०१५ व दि.०४.०१.२०१६ अन्वये शासनाने निर्देश दिलेले आहेत, (यापुढे ज्यास "उक्त शासन निर्णय" असे संबोधले आहे), व त्याअनुषंगाने शासनाने "प्रस्ताव छाननी समिती" गठीत केली आहे;

आणि ज्याअर्थी, उक्त अधिनियमाचे कलम २० पोट कलम (२) मधील तरतूदीनुसार, उक्त जमीनी, 'भागशः वनीकरण विभागातून व भागशः शेती तथा ना विकास विभागातून वगळून खालील अटींच्या अधीन राहून, 'औद्योगिक विभागात' समाविष्ट करण्याचे प्रस्तावित असून, त्या अनुषंगाने उक्त प्रादेशिक योजना सुधारित करणे आवश्यक आहे. (यापुढे ज्यास "उक्त फेरबदल" असे संबोधले आहे), असे उक्त शासन निर्णयान्वये गठीत "प्रस्ताव छाननी समिती" चे मत झाले आहे;

अटी-

१) शासन निर्णय दि.०६.०५.२०१५ व दि. ०४.०१.२०१६ तसेच या अनुषंगीक शासन निर्णयातील सर्व अटी / शर्ती, जमिनधारक/विकसक यांचेवर बंधनकारक राहतील.

२) सदर प्रस्तावामध्ये खालीलप्रमाणे समिती सदस्यांचे अभिप्राय प्राप्त झाले आहेत.
i: मा. जिल्हाधिकारी पुणे, दि. ०५.०७.२०२६,
ii. मुख्य अभियंता, महाराष्ट्र जीवन प्राधिकरण प्रा. वि. पुणे दि. ०६.०३.२०२६,
iii. मुख्य अभियंता, सार्वजनिक बांधकाम प्रा.वि. पुणे दि. १३.०४.२०२६,
iv. मुख्य अभियंता, जलसंपदा, प्रा. वि. पुणेः- दि.०५.०५.२०२६.
v. सहायक संचालक, नगररचना, पुणे शाखा दि.२१.०७.२०२६
vi. संचालक, नगर रचना, महाराष्ट्र राज्य, पुणे, दि.०१.०९.२०२६
उपरोक्त समिती सदस्यांच्या पत्रांमधील सर्व नमूद अटी / शर्ती जमिनधारक/विकासक यांचेवर बंधनकारक राहतील.

३) विषयांकीत फेरबदल प्रस्ताव, १) मौजे मंगरूळ, ता. मावळ, जि.पुणे येथील
अ) गट नं. ३०पै., ३९पै, ४०पै मधील ४.११९२ हे. आर क्षेत्र भागशः शेती तथा ना विकास विभागातून औद्योगिक विभागात,
ब) गट नं. ३०पै., ३९पै, ४०पै, ४१ पै., ४६ पै., ४८, ४९/१ पै., ४९/२ पै. मधील १५.९६४२ हे. आर वनीकरण विभागातून शेती विभागात व शेती विभागातून औद्योगिक विभागात,
ii) मौजे नवलाख उंबरे, ता. मावळ, जि.पुणे येथील गट नं. ४५० पै मधील ३.०९२४ हे. आर. क्षेत्र वनीकरण विभागातून शेती विभागात व शेती विभागातून औद्योगिक विभागात समाविष्ट करणे,
उपरोक्त i) अ व ब ii) चे क्षेत्र २३ हे. १७.५८ आर बाबतचा बदल असल्यामुळे शासन निर्णय क्र.टिपीएस-१८१५/प्र.क्र.४९/१५/नवि-१३, दि. ०४/०१/२०१६ मधील मुद्दा ७.२.२ - विभाग बदलासाठी अधिमूल्य आकारावयाचे कार्यपद्धतीनुसार तक्त्यामधील क्र.५ प्रमाणे वनीकरण विभाग ते शेती विभागातील क्षेत्रासाठी २०% व तक्त्यामधील क्र. १ प्रमाणे शेती विभाग ते औद्योगिक विभागातील क्षेत्रासाठी ३०% असे एकूण ५०% अधिमूल्य रक्कम अर्जदार यांनी महाराष्ट्र प्रादेशिक नियोजन व नगर रचना अधिनियम १९९६ चे कलम २०(४) अन्वये अंतिम मान्यतेपूर्वी भरणे बंधनकारक राहिल.

४) एकत्रिकृत विकास नियंत्रण व प्रोत्साहन नियमावलीतील तरतूदीनुसार आवश्यक १०% खुली जागा क्षेत्राव्यतिरीक्त १०% क्षेत्र औद्योगीक सुविधा भूखंड प्रस्तावित करणे अर्जदारावर बंधनकारक राहील.

आणि ज्याअर्थी, शासनाने उक्त अधिनियमाचे कलम १५१ पोटकलम (१) अन्वये निर्णय क्र.टिपीएस-१८१५/प्र.क्र.४९/१५/नवि-१३, दि. ११.६.२०१५ नुसार उक्त अधिनियमाचे कलम २० (२), २० (३) व २० (४) खालील अधिकार विभागीय सहसंचालक, नगर रचना यांना प्रदान केलेले आहेत;

आणि त्याअर्थी, याबाबतीत शासनाने प्रदान केलेल्या अधिकारानुसार, उक्त अधिनियमाच्या कलम २० चे पोटकलम (३) अन्वये, सहसंचालक, नगर रचना, पुणे विभाग, पुणे उक्त प्रादेशिक योजनेत उक्त फेरबदल करण्याचा हेतू या सूचनेव्दारे घोषीत करीत असून उक्त प्रस्तावित फेरबदलाच्या अनुषंगाने नागरिकांकडून सूचना / हरकती, ही सूचना महाराष्ट्र शासन राजपत्रात प्रसिध्द झाल्याच्या तारखेपासून ३० दिवसांच्या मुदतीत लेखी स्वरुपात मागविण्यात येत आहेत;

हरकती / सूचना सहायक संचालक, पुणे शाखा, पुणे, नवीन प्रशासकीय इमारत, विंग डी, ३रा मजला, पूर्व बाजू, विधान भवनासमोर, पुणे- ४११ ००१ यांच्या कार्यालयाकडे पाठवाव्यात. उक्त प्रस्तावित फेरबदल दर्शविणारा नकाशा नागरिकांच्या अवलोकनार्थ त्यांचे कार्यालयात कार्यालयीन वेळेत उपलब्ध आहे. प्रस्तुत फेरबदलाबाबत विहीत मुदतीत प्राप्त होणाऱ्या सूचना / हरकतींवर सुनावणी देण्यासाठी व वैधानिक कार्यवाही पूर्ण करुन त्यांचा अहवाल सदस्य सचिव यांचेकडे सादर करण्यासाठी सहायक संचालक, पुणे शाखा, पुणे यांना " अधिकारी" म्हणून प्राधिकृत करण्यात येत आहे.

प्रस्तुत सूचना www.dtp.maharashtra.gov.in या संकेतस्थळावर उपलब्ध आहे.

सही/-
(प्र.सो. गायकवाड)
सदस्य सचिव, प्रस्ताव छाननी समिती
तथा
सहसंचालक, नगर रचना,
पुणे विभाग, पुणे.

DGIPR 2026-27/3758

साखर कारखान्यांच्या नफ्यात घसरण?

दिल्ली, नवराष्ट्र न्यूज नेटवर्क. चालू आर्थिक वर्षात भारतीय साखर कारखान्यांच्या परिचालन नफ्याचे प्रमाण १.४ ते १.६ टक्क्यांनी घटण्याचा अंदाज आहे. ऊसापासून इथेनॉल निर्मितीवर घातलेल्या निर्बंधांमुळे, अधिक नफा मिळवून देणाऱ्या महसुलाच्या एका महत्त्वाच्या स्रोतावर परिणाम झाला आहे. याव्यतिरिक्त, ऊसाच्या वाढत्या किमती आणि वाढलेली आर्थिक गरज यामुळे साखर कारखान्यांवर अतिरिक्त दबाव निर्माण झाला आहे, असे 'क्रिसिल रेटिंग्ज'च्या अंदाजात म्हटले आहे.

क्रिसिलच्या मते, चालू आर्थिक वर्षात साखर कारखान्यांचे परिचालन नफ्याचे प्रमाण सुमारे ६ टक्क्यांपर्यंत खाली येऊ शकते, तर दुसरीकडे त्यांचा एकूण महसूल ४ ते ५ टक्क्यांनी वाढण्याची शक्यता आहे. साखरेचे भक्कम दर आणि स्थिर मागणी असूनही, उत्पादनांचे बदललेले स्वरूप, कच्च्या मालाचा वाढता खर्च आणि व्याजाचा वाढता बोजा भरून काढण्यासाठी हे पुरेसे ठरणार नाही.

D S KULKARNI DEVELOPERS LIMITED
CIN: L45201PN1991PLC063340
Regd. Office: Unit 301, 3rd Floor, Swojas One, Kothrud, Pune - 411038
Phone No.: 020-67166716 • Email: cs@solitaire.in • Website: www.dskcirp.com

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 2026

(Amount in lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)	Quarter ended (Unaudited)	Half Year ended (Unaudited)
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	September 30, 2026
Total income from operations (net)	5,714.75	1,401.21	1,414.10	7,115.96	2,812.83	5,617.32	1,414.75	2,815.